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Abstract

Physicochemical modulation of huntingtin aggregation on lipid membranes: Implications
for Huntington's disease

Maxmore Chaibva

Huntington disease is a genetic, neurodegenerative disease caused by an expanded
polyglutamine (polyQ) in the first exon of the huntingtin (htt) protein, facilitating its aggregation,
leading to the formation of a diverse population of potentially toxic aggregate species, such as
oligomers, fibrils, and annular aggregates. Htt interacts with a variety of membranous structures
within the cell, and the first seventeen amino acids (Nt17) of htt directly flanking the polyQ
domain is an amphipathic α-helix (AH) lipid-binding domain. AHs are also known to detect
membrane curvature. Nt17also promotes diverse aggregate species of htt and undergoes a number
of posttranslational modifications that can modulate htt’s toxicity, subcellular localization, and
trafficking of vesicles. To get in-depth mechanistic insights of huntingtin aggregation, both
chemical and physical modulators of the aggregation process were explored. Specifically, the
importance of htt acetylation and the role of membrane curvature on htt aggregation were
investigated using atomic force microscopy (AFM), which has become a robust technique to
obtain physical insights into the formation of toxic protein aggregates associated with amyloid
diseases on lipid membranes. Acetylation of htt exon 1, and synthetic truncated htt exon1
mimicking peptide (Nt17Q35P10KK) was achieved using a selective covalent label sulfo-Nhydroxysuccinimide (NHSA) in molar ratios of 1x, 2x, and 3x NHSA per peptide. Htt
acetylation was found to decrease fibril formation in solution and promoted the formation of
larger globular aggregates. Acetylation strongly altered htt’s ability to bind lipid membranes.

However, one of the several limitations associated with using these current flat, supported
bilayers as model surfaces is the absence of membrane curvature, which can heavily influence
the interaction of proteins at lipid interfaces. Using an AFM force reconstruction technique,
silicon substrate, and silica nanobeads, model lipid bilayer system was developed and validated
in which the underlying solid support is comprised of flat and curved regions to induce regions
of curvature in the bilayer. This model bilayer system was exposed to Nt17Q35P10KK peptide, and
this peptide preferentially bound and accumulated to curved membranes, consistent with the
ability of AHs to sense membrane curvature.

Dedication
I dedicate this Ph.D. dissertation to my wife, Faith Ruzvidzo Chaibva , my two boys
Donnel Tavonga , and Shiloh Nenyasha Chaibva. You were my inspiration.

Faith, thank you for your unconditional support, prayers, and for taking care of the kids
during these five years. You always stood by me. You left your professional and came to
USA with me. You were a stay home mum for 5 years while I was studying. You are
awesome.

“Whatever you vividly imagine, ardently desire, sincerely believe and enthusiastically act
upon must inevitably come to pass.”
― Paul J. Meyer

iv
Dedication

Acknowledgements
My deepest gratitude goes to my Ph.D advisor, Dr. Justin Legleiter for his
support, encouragement, and scientific freedom during my graduate studies in his
research lab. He gave me invaluable opportunities to troubleshoot technical and
experimental questions that arose during my experiments, as well as opportunities for
developing lab protocols. He also presented me with challenges and opportunities to
write research reviews and book chapters so that I get credit which would otherwise have
gone to him alone. If I am given a second chance to choose a Ph.D advisor, I would still
go with Justin Legleiter. I am truly grateful for his patience, motivation, and mentorship.
I would like to thank West Virginia University, C. Eugene Bennett Department of
Chemistry for providing me with a doctoral scholarship, and the additional funding
agencies, including NIH, WVU NanoSafe who funded this work. I would also like to
thank my committee members; particularly Dr. Visvanathan Ramamurthy and his
graduate student, Abigail Hayes, for their help and guidance in reconstructing the new
huntingtin protein constructs to fix the mutation on protein. Special mention goes to my
collaborator Dr. Silvina Matysiak for performing computational studies to help obtain
mechanistic details on my acetylation project.
A heartfelt thank you to all past and present Legleiter lab members, we have
always had a fantastic, encouraging and supportive group. Special thanks goes to Dr.
Kathleen .A. Burke who initially trained me on how to purify huntingtin protein and to
run PDA assays. I would also like to thank Dr. Elizabeth Yates for patiently teaching me
most aspects of AFM when I joined the lab. Special thanks go to Dr. Nicole ShamtikoKlingensmith for being a special friend and more like a sister, and for teaching me other
v
Acknowledgements

important aspects of AFM simulations, and Photoshop. Additional thanks to one of the
undergraduate student, Pranav Jain. I also thank Dr. James Arndt for helping me with
mass spectrometry analysis on one of my projects. Lastly, I would like to thank other lab
members (Xiang Gao, Pilkington IV, Sharon Groover, Adewale Adegbuyiro, Faezeh
Sedighi for your love and support
Finally, I thankful for such a loving and caring wife, Faith Ruzvidzo Chaibva,
who is always able to put a smile on my face. She always believed in me, even when I
didn’t believe in myself. I would not have made it through the graduate school without
her unwavering and unconditional love, and support. I am also thanking my parents
(Ishmael and Junior Chaibva) who raised me as a hard worker and sent me to school with
their hard earned money. My siblings (Robina, Xavier (late), Aaron, Darlington and
Luxton) also played an important role in my education.

Above all, I would like to thank God almighty who gave me the opportunity to
come to WVU to purse a funded Ph.D program and gave me creative ideas in my
graduate studies.

vi
Acknowledgements

Table of Contents
Abstract......... ....................................................................................................................................... ii
Dedication............................................................................................................................................ iv
Acknowledgments………………………………………………………………….. ......................... iv
Table of Contents………………………………………………………………….. ......................... vii
List of Figures ......................... ……………………………………………………………………....xi
List of Tables ......................... ………………………………………………………………………xiv
List of Abbreviations ........................ ………………………………………………………………xiv
1. Protein aggregation and Huntington’s disease ............................................................................. 1
1.1

Neurogedenerative diseases ............................................................................................. 1

1.2

Huntington’s disease ........................................................................................................ 2

1.3

Protein aggregates in HD ................................................................................................. 4

1.4

The first seventeen amino acids of huntingtin (Nt17) ....................................................... 7

1.4.1

Biophysical and biochemical properties of Nt17 ............................................................. 8

1.4.2

Nt17 as a potential therapeutic target on htt exon 1 ......................................................... 9

1.4.3

Post translational modifications in Nt17......................................................................... 11

1.4.4

Nt17 mediates huntingtin/lipid interactions with potential implications for
toxicity. .. ........................................................................................................................ 14

1.5
1.6

Lipid Composition in huntingtin/lipid interaction.......................................................... 17
Dissertation Outline and Study Rationale ...................................................................... 18
vii

Table of contents

1.7

Atomic Force Microscopy (AFM) ................................................................................. 19

1.8

References ...................................................................................................................... 21

2. Scanning probe acceleration microscope and the development of supported bilayers
with curvature .............................................................................................................. 42
2.1

Introduction .................................................................................................................... 43

2.2

Numerical model of the entire imaging process of TMAFM in solution ....................... 46

2.3

Basic principles underlying SPAM ................................................................................ 50

2.4

Features of the time-resolved tip/sample force are independent of surface
topography………… ...................................................................................................... 52

2.5

Application of SPAM ..................................................................................................... 54

2.6

SPAM in the development of supported lipid bilayers with curvature .......................... 56

2.6.1

Preparation of total brain lipid extract ........................................................................... 56

2.6.2

Preparation of poly-L-lysine coated silicon substrate .................................................... 57

2.6.3

Nanoparticles deposition on silicon substrate ................................................................ 57

2.6.4

In situ AFM and SPAM imaging conditions .................................................................. 58

2.7

Results ............................................................................................................................ 59

2.7.1

Development of a system of supported flat and curved lipid bilayers ........................... 59

2.7.2

Validating bilayer formation on beads using imaging forces ......................................... 62

2.8

Discussion ...................................................................................................................... 67

2.9

Conclusion ...................................................................................................................... 68

viii
Table of contents

2.10

References ...................................................................................................................... 69

3. Curvature enhances binding aggregation of huntingtin in lipid membranes .......................... 75
3.1

Introduction:Huntington’s disease and importance of membrane curvtaure ................. 76

3.2

Materials and Methods .................................................................................................. 78

3.2.1

In situ AFM imaging conditions .................................................................................... 78

3.2.2

Peptide preparation ......................................................................................................... 79

3.3
3.3.1

Results ............................................................................................................................ 79
Htt peptides preferentially bind to curved bilayers ........................................................ 79

3.4

Discussion ...................................................................................................................... 87

3.5

Conclusion ...................................................................................................................... 90

3.6

References ...................................................................................................................... 90

4. Acetylation within the first 17 amino acids of htt exon1 alters aggregation and
binding to lipid membranes .. ...................................................................................... 99
4.1

Introduction: Huntingtin disease and post translational modifications ........................ 100

4.2

Materials and Methods ................................................................................................. 102

4.2.1

Peptide preparation. ...................................................................................................... 102

4.2.2

Liquid Chromatography/Tandem Mass Spectrometry ................................................. 103

4.2.3

Thioflavin T (ThT) assay ............................................................................................. 104

4.2.4

Purification of GST-htt-exon1 fusion proteins ............................................................. 105

4.2.5

Acetylation of htt exon1 .............................................................................................. 105

ix
Table of contents

4.2.6

Protein samples for ex situ AFM imaging.................................................................... 106

4.2.7

Preparation of lipid bilayers ......................................................................................... 106

4.2.8

AFM imaging conditions.............................................................................................. 106

4.2.9

Imaging Processing ...................................................................................................... 107

4.2.10 Preparation of TBLE/PDA vesicles ............................................................................. 107
4.2.11 Preparation of PDA/htt sample solutions ..................................................................... 108
4.3
4.3.1

Results ......................................................................................................................... 108
Chemically-induced acetylation occurs at all lysines in Nt17 and inhibits
aggregation. .................................................................................................................. 108

4.3.2

Acetylation of Nt17 inhibits htt-exon1 fibril formation ................................................ 110

4.3.3

Nt17 Acetylation inhibits htt/lipid interactions .............................................................. 114

4.4

Discussion .................................................................................................................... 121

4.5

Conclusion .................................................................................................................... 127

4.6

References .................................................................................................................... 128

5. Other relevant post translational modifications and small molecules as potential
modulators of huntingtin aggregation .. ................................................................... 144
5.1
5.1.1

Work in progress: GM1 modulates huntingtin aggregation on lipid membranes ........ 145
Cholesterol and GM1 alters the extent of htt-exon1 binding to lipid vesicles as
determined by TBLE/PDA binding assay acetylation occurs at all. ............................ 146

5.2

Future studies ............................................................................................................... 150

x
Table of contents

5.2.1

Post translational modifications on huntingtin aggregation ........................................ 150

5.2.2

Targeting huntingtin Nt17 with small molecules ......................................................... 151

5.3

Concluding remarks and Perspectives .......................................................................... 153

5.4

References .................................................................................................................... 155

xi
Table of contents

List of figures
Chapter 1 ............................................................................................................................1
Figure 1. A schematic model for htt aggregation ............................................................2
Figure 2. Schematic of important features of of htt exon1...............................................4
Figure 3. Basic schematic illustration of an AFM ........................................................20
Chapter 2 ..........................................................................................................................42
Figure 1. SPAM is a method for reconstructing the time-resolved tip/sample forces
associated with TMAFM imaging in solution ...............................................................45
Figure 2. Comparison of simulated cantilever position and deflection trajectories in
high Q and low Q systems .............................................................................................47
Figure 3. Simulations to determine the effect of surface topography on tip/sample
imaging forces ...............................................................................................................53
Figure 4. SPAM imaging of a supported lipid bilayer patch on mica ...........................55
Figure 5. Time-lapse AFM images taken in solution of a TBLE bilayer forming over
silica beads immobilized on silicon ..............................................................................59
Figure 6. Schematics demonstrating two potential ways the lipid bilayer could be
arranged with respect to the beads ................................................................................61
Figure 7. Tapping mode AFM simulations demonstrate the relationship between
imaging forces and surface mechanical properties ........................................................63
Figure 8. Tapping mode AFM simulations demonstrate the effect of Young's modulus
on the measured height of a 50 nm bead .......................................................................64
Figure 9. Maximum forces associated with imaging the surfaces confirm the presence
of lipid bilayers covering the beads ...............................................................................65

xii

Chapter 3 ..........................................................................................................................75
Figure 1. Time lapse AFM images taken in solution of a TBLE bilayer exposed to a
synthetic htt exon1 mimicking peptide .........................................................................80
Figure 2. AFM image shows that a synthetic htt exon1 mimicking peptide aggregates
on and disrupts the flat regions of the lipid bilayer .......................................................82
Figure 3 Three dimensional renderings of model objects with increasingly larger
volume are presented .....................................................................................................83
Figure 4. Volume of deposited synthetic htt exon 1−mimicking peptide on the curved
or flat regions of the bilayer ..........................................................................................86
Chapter 4 ..........................................................................................................................99
Figure 1. Lysines within Nt17 are accessible for acetylation and impact fibril formation
......................................................................................................................................110
Figure 2. Addition of NHSA to GST-htt-exon1 does not inhibit cleavage of the GST
tag by Factor Xa ..........................................................................................................111
Figure 3. Chemical acetylation of Nt17 in htt-exon1 suppresses aggregation .............112
Figure 4. Acetylation of Nt17 in htt-exon1 influences the size of aggregates .............114
Figure 5. Acetylation of Nt17 modulates the interaction between htt-exon1 and lipid
membranes ..................................................................................................................115
Figure 6. Exposure to htt-exon1disrupts TBLE bilayers morphologically .................117
Figure 7. Acetylation of Nt17 does not alter the size of oligomers of htt-exon1 on lipid
bilayers ........................................................................................................................120
Figure 8. Acetylation-mimicking mutations reduce the affinity of Nt17 for lipid vesicles
......................................................................................................................................121

xiii

Chapter 5 ........................................................................................................................144
Figure 1. Percent colorimetric response (%CR) of TBLE/PDA vesicles containing
various amounts of cholesterol upon exposure to htt-exon1 .......................................147
Figure 2. Percent colorimetric response (%CR) of TBLE/PDA vesicles containing
various amounts of GM1 upon exposure to htt-exon1 .................................................148
Figure 3. GM1 alters the interaction of htt with supported lipid bilayers ...................149
Figure 4. Representative AFM images of htt exon 1 at different type points after
incubation with polpP and Nt17 ...................................................................................152

xiv

List of tables

Table 1.

Estimation of the % error associated with tip convolution

84

List of symbols and abbreviations
A

cantilever tapping amplitude

Ao

cantilever free tapping amplitude,

aDMT

interatomic distance

a0

drive oscillation amplitude

AFM

atomic force microscopy

b

damping coefficient

CD

circular dichroism

% CR

percent colorimetric response

D0

resting position of the cantilever base

DLVO

Derjaguin-Landau-Verway-Overbeek

DMT

Derjaguin-Muller-Toporov

E

Young's modulus

E. coli

Escherichia coli

Fext

tip/sample tapping force

Fmax

maximum tapping force

Ftotal

total tapping force

GST

glutathione S-transferase

H

Hamaker constant

HCD

Higher-energy collisional dissociation

HD

Huntington's disease

List of abbreviations

xv

HFIP

hexafluoroisopropanol

Htt

huntingtin

htt exon1(51Q)

huntingtin exon1 with 51 glutamines

IPTG:

Isopropyl β-D-1-thiogalactopyranoside

k,

spring constant

kDa

KiloDalton

κeff

effective indentation constant

KK-Q35-P10-KK

35 glutamines followed by 10 prolines flanked by 2 lysines
on each side

K6Q

lysine mutated to glutamine

meff

mass of the cantilever

MS

mass spectrometry

NHSA

sulfo-N-hydroxysuccinimide

Nt17

the first 17 N-terminal amino acids of the huntingtin

PBS

phosphate-buffered saline

polyP

polyproline

polyQ

polyglutamine

PTMs

post translational modifications

PDA

polydiacetylene

Q

quality factor of the cantilever

Rtip

radius of the cantilever tip

RMS

root mean square

S

set-point ratio

List of abbreviations

xvi

SPAM

scanning probe acceleration microscopy

TBLE

total brain lipid extract

TFA

trifluoroacetic acid

ThT

thioflavin T

TMAFM

tapping mode atomic force microscopy

Tris

Tris(hydroxymethyl)aminomethane

Ω

drive frequency

ωο

resonance frequency

ωoper

operating frequency

x

cantilever deflection

y

cantilever deflection

z

position of the cantilever with respect to the surface

List of abbreviations

xvii

1. Protein aggregation and Huntington’s disease 1

1.1 Neurodegenerative diseases
The molecular pathway associated with a vast number of neurodegenerative
diseases, including Huntington’s disease (HD), Alzheimer’s disease (AD) and
Parkinson’s disease (PD), is characterized by protein misfolding, resulting in the
aggregation of the misfolded protein, and its deposition, and accumulation in cellular
compartments as nanoscale aggregates [1, 2]. Proteins are synthesized as linear chains of
several amino acids, and most properties adopt a well-defined three dimensional compact
structure during folding for them to be functional. The main driving force for protein
folding is the tendency for hydrophobic residues within the protein surface to interact
together rather than with water, a phenomenon known as the hydrophobic effect. This
leads to the burial of nonpolar side chains in the interior of proteins, leading to the
“collapse” of the protein from an extended coil to a more defined, globular structure.
Proteins are at risk of misfolding in which a protein is trapped in a local energy minimum
and become misfolded. These misfolded proteins can follow a complex pathway that
leads to the formation of fibrils rich in β-sheet structures via intermediate species such as
oligomers (Fig. 1), and these aggregates will eventually accumulate as inclusions in the
brain of diseased victims. The deposition of these inclusion bodies is the hallmark of
many neurodegenerative diseases. It remains controversial whether the small, potentially
diffusible assemblies, or mature amyloid fibrils, are primary culprits in neuronal
dysfunction and death [3-5].
1
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Emerging Role of the First 17 Amino Acids of Huntingtin in Huntington’s disease.
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Figure 1. A schematic model for htt aggregation. A native monomer can sample a
variety of distinct, misfolded monomer conformations. There appears to be to generic
aggregation pathways toward the formation of fibrils structures. One of these pathways
proceeds through oligomeric intermediates (A), some of which may be facilitated by
Nt17. Oligomerization can also lead to the formation of large amorphous aggregates. All
of these higher order aggregates may accumulate together to form the large inclusions
that are a hallmark of HD.

In this introductory chapter, the Huntington’s disease protein will be discussed, including
the role of the protein’s first seventeen amino acids on modulating its aggregation,
kinetically and morphologically on lipid membranes.

1.2 Huntington’s disease (HD)
HD is a fatal, progressive neurodegenerative disorder with well-established
origins and affects specific neurons in the brain. This monogenic disorder is caused by a
single mutation in the IT15 gene that code for Huntington protein, huntingtin (htt). The
1.
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mutation occurs as a CAG trinucleotide expansion in the gene. CAG codes for the amino
acid glutamine, and therefore, the mutation leads to an expansion of a polyglutamine
(polyQ) tract near the N-terminus of the protein htt [6]. This polyQ expansion directly
leads to htt aggregation into fibrils and a variety of other aggregates [7-9], as shown in
Fig. 1. While the exact mass of htt is dependent on the size of the polyQ domain, fulllength htt consists of 3144 amino acids (figure full length), 67 exons, and is
approximately 350 kDa in weight [6]. The polyQ domain begins at the 18th residue of htt
and is contained in exon 1. For the studies presented here, the htt fragment (htt exon1) not
the full protein was used .Several lines of evidence suggested that N-terminal fragments
comparable to exon 1 are directly involved in HD [10-15]. For instance, expression of htt
exon1 with an expanded polyQ tract causes a progressive neurological phenotype
(including incoordination, gait instability, cognitive abnormality, weight loss, progressing
to early death) in R6/2 transgenic mice [13, 16]. More recent studies demonstrated that,
N-terminal fragments comparable to exon1 are detected in knock-in mouse models
expressing full length htt [14], and fragments of the size of exon1 have been detected in
HD patients [17]. Finally, it has not been possible to recombinantly express and purify
the full htt protein. The polyQ domain is flanked by the first 17 amino acids at the Nterminus (Nt17) of the protein and by a polyproline (polyP) stretch on its C-terminal side
(Fig.2a). One of the key aspects of HD is that there is a threshold length of the polyQ
domain required for disease with a tight correlation between both the age of onset and
severity of disease with the increasing length of the polyQ expansion. Specifically,
individuals with CAG repeat lengths less than 35 in their DNA sequence will not get the
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Figure 2. Schematic of important features of of htt exon1, with (a), showing Nt17
(purple), polyQ (red) and the polyP (blue) regions. b) View down the barrel of the αhelix showing relative hydrophobicity of each residue as well as the sites of reported
posttranslational modifications. The colors on (a) don’t correspond to (b)
disease, 35–39 repeats may elicit disease, 40–60 repeats cause adult onset, and juvenile
forms of HD are associated with repeats greater than 60 [18-20]. Symptoms typically
begin between 35-50 years, followed by 15-20 years of progression before death [21].

1.3 Protein aggregates in HD
The role of aggregates in HD is a complex issue and remains to be clearly
understood. Biochemically and biophysically, it has been demonstrated that htt fragments
containing expanded polyQ tracts readily form detergent-insoluble protein aggregates
with characteristics of amyloid fibrils [22, 23]. Furthermore, the rate of aggregation into
1.
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fibrils is highly correlated with polyQ length in synthetic peptides and htt exon1
fragments [24]. This correlation between aggregation rate and polyQ length has been
recapitulated in cell culture models expressing htt fragments [25-27]. While it is clear that
htt with expanded polyQ tracts assemble into fibrils, htt also forms spherical and annular
oligomeric structures [9, 28, 29]. It is therefore evident that htt can form a variety of
aggregate structures; however, the precise mechanisms by which these structures induce
toxicity and neurodegeneration is unclear. Precise characterization of the possible
aggregation pathways and the resulting heterogeneous mixtures of aggregates, as well as
factors that modulate protein aggregation is a vital step in understanding htt aggregation.
Extensive research has been performed to determine the kinetics of htt
aggregation and to determine specific aggregate species on and off pathway to fibril
formation [24]. In this regard, several aggregation pathways have been proposed for the
formation of fibrils of polyQ-containing proteins. Two of the more prominent
aggregation schemes are: 1) re-arrangement of a monomer to a thermodynamically
unfavorable conformation that directly nucleates fibril formation and 2) the formation of
soluble oligomeric intermediates that slowly undergo structural re-arrangement into a βsheet rich structure leading to fibrils (Fig. 1). The precise nature of the oligomeric
aggregates associated with the second scheme can be quite heterogeneous [30, 31], and
there could be a variety of oligomeric species that are off-pathway to fibril formation.
While polyQ peptide fibrils share many classical features associated with amyloids,
initial reports using pure polyQ peptides supported the nucleation-elongation model for
the formation of polyQ fibrils [32, 33]. Subsequent studies have suggested other potential
mechanisms associated with the potential of smaller aggregates of polyQ proteins
1.
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appearing prior to nucleation of fibril formation [34, 35]. Small oligomers, displaying
various degrees of stability, of polyQ peptides with various glutamine lengths were
observed by atomic force microscopy (AFM) [7]. Studies of polyQ peptides that were
interrupted by other amino acids further support the formation of oligomers [36]. While
many oligomers were observed to directly initiate fibril formation when individually
tracked in solution, many fibrils appeared to form without any obvious oligomeric
precursors [7]. Such observations suggest that these aggregation pathways are not
mutually exclusive, making the situation considerably more complicated. AFM studies of
a variety of htt-exon 1 fragments have shown that aggregation reactions result in
heterogeneous mixtures of distinct aggregate morphologies in a polyQ length- and
concentration-dependent manner [7]. Novel oligomers of htt exon1 have also been
identified in an in vitro mammalian system [30]. Due to the complexity of htt
aggregation, there is no clear consensus on the aggregate form(s) that underlie toxicity,
and there likely exist bioactive oligomeric aggregates undetectable by traditional
biochemical and electron microscopic approaches that precede symptoms. While
identification of the toxic specie(s) of htt that trigger neurodegeneration in HD remains
elusive, such species might exist in a diffuse, mobile fraction rather than in inclusion
bodies [37].
Mutant htt is detected in patients’ brains predominantly as microscopic inclusion
bodies in the cytoplasm and nucleus [13]; however, htt is also associated with a variety of
membranous organelles, including mitochondria, endoplasmic reticulum, tubulovesicles,
endosomes, lysosomes and synaptic vesicles [16, 38-41]. The precise mechanisms by
which htt aggregates are toxic to neural cells, leading to the extensive cellular destruction
1.
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that is the hallmark of HD, remain unclear. As a result, there is a pressing need to
understand factors that modulate htt aggregation, contribute to pathogenesis, and could
potentially serve as therapeutic targets. The Nt17 could be very important in modulating
htt aggregation.

1.4 The first seventeen amino acids of huntingtin (Nt17)
A potential mechanism by which Nt17 influences toxic htt aggregation is that the
formation of abnormal aggregates of mutant htt is directly influenced by this domain.
Indeed, Nt17 has been implicated in driving the initial phases of htt exon 1 interaction [39,
42-45]. Several mechanisms have been proposed that are mediated by Nt17. Most agree
that the initial phase of aggregation when Nt17 is present begins with self-association of
this domain, resulting in the formation of small, α-helix rich oligomers [46-48]. As such,
it appears that Nt17 promotes fibril formation via the oligomer mediated pathway. In a
cellular environment, pathogenic htt exon 1 oligomer populations do not appreciably
change even with recruitment of monomers into inclusion bodies, suggesting that the
formation of oligomeric species mediated by Nt17 is the rate-determining step [49, 50].
Since oligomers are widely considered to be the toxic species in Huntington’s disease, the
promotion of oligomerization by Nt17 could have potentially important consequences of
htt-related toxicity. PolyQ peptides that do not have the N-terminal flanking sequence
tend not to form oligomeric intermediates and as a result, proceed directly to fibrillar
aggregates [51, 52]; although, some pure polyQ-peptide oligomers have been observed to
form when aggregating on a surface [7, 53]. The addition of a myc-tag preceding Nt17 in
full htt exon 1 reduces the formation of oligomers in vitro without changing the rate of
1.
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fibril formation when compared to exon 1 proteins of similar polyQ length that lacked
this myc-tag [54], suggesting that the ability of Nt17 to promote oligomerization can be
interfered with by steric hindrances. Such findings seem to suggest that Nt17 could a good
target for therapeutic intervention.

1.4.1 Biophysical and biochemical properties of Nt17
The Nt17 domain can form an amphipathic α-helix (AH) that is conserved in at
least some aggregate forms of htt [44, 52, 55]. There are several important biophysical
properties associated with AHs [56], but in particular, AHs are often associated with
binding of lipid membranes [57, 58]. Briefly, an AH consists of a predominately
hydrophilic face and a predominately hydrophobic face (Fig. 2b). AHs have been shown
to have several functional properties such as preferentially sensing and binding highly
curved membrane by detecting defects induced by curvature [59]. Due to their ability to
weakly bind membranes, their interaction with membranes is easily regulated. Nt17 has
been shown to sequester truncated htt exon1 peptides to regions of curvature on
supported lipid bilayers [60]. The structure of an AH is compatible with the formation of
a variety of helix bundles in aqueous environment that is driven by maximizing the
interaction of the hydrophobic faces of adjacent helices [61, 62]. Due to this, the
association of Nt17 via the formation of interacting AHs has been proposed to play a role
in the initial stages of htt aggregation. The Nt17 primary sequence contains three
positively charged lysine residues at positions 6, 9, and 15. Residues 6 and 15 lie at the
boundary between the hydrophilic and hydrophobic faces in a theoretical AH that extends
the entire length of Nt17 (Fig. 2b). Additionally, two methionine, two serine, and two
1.
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glutamic acid residues also reside on the hydrophilic face. The hydrophobic face consists
of two phenylalanine residues, three leucine residues, and an alanine residue, with a
leucine and a phenylalanine at each side of the boundary. It would appear that residues in
the boundary region are critical in lipid membrane binding and intermolecular interaction.
Simulation of lipid membrane association show K6 and K15 are strong hydrogen bond
donors with lipid bilayers [63]. Similarly, K6 was found to be protected from an
aggregated state by solution phase deuterium exchange mass spectrometry [64]. These
studies point to critical interactions involving amphipathic helices that can potentially be
involved in the formation of the previously mentioned oligomeric precursors to fibril
formation that are mediated by Nt17. Compelling evidence demonstrates that the α-helix
is conserved in fibrils [44, 64, 65]. Additionally, ssNMR chemical shifts indicate residues
4 – 11 are in an α-helical arrangement within a fibril structure, while residues 17 – 19
have a clear β-sheet structure [44]. While there is little doubt that Nt17 is capable of
forming an AH, under what conditions Nt17 adopts this structure in monomeric htt and
the related consequences for aggregation are of critical importance.
1.4.2 Nt17 as a potential therapeutic target on htt exon 1
From the ongoing discussion, it is clear that Nt17 has been implicated in the
formation of the toxic intermediates, it represents a novel target to inhibit (or alter)
aggregate formation, thereby possibly alleviating htt-mediated toxicity. A more practical
means of inhibiting N-terminal aggregation is through structural complexation, either by
small molecules, molecular chaperones or an antibody-antigen that interacts directly with
this domain [66-71]. Interestingly, free Nt17 (lacking any polyQ) has been used to inhibit
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Nt17-mediated formation of Nt17Q37P10K2 peptides in vitro [51, 52]. The mechanism by
which Nt17 inhibits amyloid formation appears to be identical to the mechanism by which
nucleation occurs, with the caveat that Nt17 alone does not contain an amyloidogenic
polyQ tract. This increases the distance between adjacent polyQ tracts and the energy for
polyQ fibrillization to occur [52]. It has also been known for some time that molecular
chaperones can modulate htt aggregation [72, 73]. Many of these molecular chaperones,
including Hsc79 [74] and Tric [68, 69], have been shown to bind directly to Nt17.
Specifically ,it was found out that an intrinsically disordered chaperone, HYPK interacts
with Nt17 in htt and modulates aggregate formation and cytotoxicity in neuronal cell lines
[75].
Another potential therapeutic strategy that has been extensively studied is the use
of antibodies; unlike peptide therapeutics and inhibitors, antibodies are specific only for
the target antigen. Several antibodies exist for htt exon 1, each recognizing distinct
domains and potentially distinct monomers or aggregates [31, 76-79]. In the past decade,
intracellular antibodies, or intrabodies, for Nt17 have been developed that inhibit htt exon
1 fibrillization and cytotoxicity in vitro and cellular huntingtin model, two of which are
scFv and VL 12.3.[66, 67, 80]. When co-transfected with htt exon 1 (104Q) into COS-7,
BHK-21, and HEK-293 cells, C4 scFv was shown to decrease aggregate formation
relative to control groups that were not transfected with the intrabody [80]. C4 scFv
bound to htt exon 1 structures of non-pathogenic length (25Q), as well, which indicates
the polyQ conformation does not play a role in intrabody binding, and that the most likely
binding target is Nt17 [80]. These studies show that structural inhibition of Nt17 is
certainly a viable means of inhibiting aggregation and, potentially, htt exon 1 toxicity.
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1.4.3 Post translational modifications (PTMs) in Nt17
Nt17 also contains numerous sites that can be post-translationally modified, with
some sites associated with multiple potential modifications (Fig. 2b) [81-83]. These
PTMs appear to have a profound effect on htt function and translocation [84-86], as well
as toxicity associated with htt containing expanded polyQ domains [81, 82, 87-89]. Most
prevalent forms of PTMs occurring in Nt17 are phosphorylation [43, 89-92], acetylation
[93], ubiquitination [94] , and SUMOylation [81, 87]. Other htt modifications such as
palmitoylation [95] and transglutamination [96] have also been observed.
The htt Nt17 domain has three potential phosphorylatable sites: threonine 3,
(Thr3), serine 13 (Ser13), and serine (Ser16) (full length htt can also be phosphorylated at
serine residues downstream from the N terminal domain. Numerous studies have reported
that htt phosphorylation is associated with reduced levels of mutant htt toxicity [83, 89,
91, 92, 97-99]. Mutating Thr3 to aspartate to mimic phosphorylation enhances the
propensity of htt to aggregate in cultured cells and resulted in reduced lethality and
neurodegeneration in Drosophila models of HD [89]. Htt containing phospho-serine
residues at 13 and 16 aggregate in a similar fashion to serine to aspartate phosphomimetic
mutations, demonstrating that serine phosphomimetic mutations are valid mimics for
studying the impact of htt phosphorylation on aggregation. Using a variety of
combinations of serine phosphorylation mimics, it was established that serine to aspartate
mutations significantly slows the formation htt aggregates and reduces the stability of the
fibril structure [43, 92]. When Ser13 and Ser16 were mutated to aspartate in the Nt17
domain of transgenic mice that expresses full length htt with 97Q, visible htt inclusions
1.

Introduction
11

within the brain were reduced, and HD–like behavioral phenotypes were reduced at 12
months of age [92]. Altering the phosphorylation state of htt (specifically at Ser13)
indirectly can also impact expanded htt related toxicity, as casein kinase 2 inhibitors
reduced Ser13 phosphorylation with a subsequent enhancement of htt-related toxicity in
high content live cell screenings [100]. Furthermore, ganglioside, GM1, triggers htt
phosphorylation at Ser13 and Ser16, diminishing htt toxicity while restoring normal
motor behavior in transgenic mice [90]. Collectively, this finding further support the
notion that Nt17 plays an important role in htt aggregation and, more specifically, that
altering the phosphorylation state of Nt17 may be a viable therapeutic strategy.
Htt can also undergo SUMOylation, ubiquitination, and acetylation on specific
lysine residues within Nt17. These potential sites include lysine residues at position 6, 9,
and 15. SUMOylation, specifically, has been implicated in both cell and animal models to
be involved in HD pathogenesis [81, 87]. SUMOylation at lysine 6 (K6) and lysine 9
(K9) stabilizes htt exon1 fragments, reducing aggregation in cultured cells and
exacerbating toxicity in Drosophila HD models [81]. Rhes, a small G protein,
preferentially binds mutant htt over wild type and acts as a SUMO E3 ligase [101]. The
subsequent SUMOylation by Rhes increases soluble levels of htt and enhances
neurotoxicity [101]. Ubiquitination is known to compete for the same lysine residues as
SUMOylation, but functionally, it is associated with tagging proteins for degradation by
the ubiquitin proteasome system (UPS), thereby reducing the toxicity of the mutant htt
[102]. However, the presence of ubiquitin in neuronal intranuclear inclusions in the HD
striatum and cortex shows that the detoxification mechanisms by ubiquitination is
incomplete for most proteins [16]. Proteomic mapping by MS verified within Nt17 that
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K9 is appreciably acetylated in mammalian cell lysates [103]. While the role of K9
acetylation has not yet been fully evaluated, acetylation of lysine 444 (K444) has been
implicated in autophagic removal of mutant htt for clearance leading to neuroprotection
in C.elegans HD model [93]. Perhaps, acetylation within Nt17 plays a similar role, but the
impact of acetylation within Nt17 on aggregation and toxicity of htt has not been fully
elucidated.
Finally, PTMs can occur in tandem, directly affecting other PTMs. For instance,
htt SUMOylation can be modulated by phosphorylation, explaining why Ser13 and Ser16
phosphomimics in htt were found to modulate SUMO-1 modification both in cells and in
vivo [91, 92]. SUMOylation is a transient process, and Nt17 lysines are predicted as low
probability SUMO sites. Therefore, one way to enhance Nt17 SUMO-1 modification is to
use serine phosphomimetic mutants [87]. Interestingly, these phosphomimics also
promote K6 htt SUMOylation, which may represent one way to regulate K9 acetylation
[87]. SUMOylation and ubiquitination can also influence each other by competing for the
same Nt17 lysine 6, 9 and 15 [81] , implying that one modification could be used to
control or enhance the other. Understanding how Nt17 PTMs impact htt and modulate
each other could lead to therapeutic intervention with the potential implications to HD.
Here, the acetylation of htt and its role in modulating htt aggregation will be presented.
1.4.4

Nt17mediates

htt/lipid

interactions

with

potential

implications

for

toxicity.
Another potential role of Nt17 in htt-related toxicity is that Nt17 directly dictates
whether, and to what extent, toxic protein aggregates interact with cellular and
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subcellular compartments, such as organelles. These interactions would be mediated by
Nt17's ability to bind membranes comprised predominately of lipids and could play an
important role in htt trafficking. These membranes may also be direct targets of htt
aggregates, that is, htt aggregates may alter membrane structure and stability as part of a
molecular mechanism of toxicity. A considerable number of observations directly and
indirectly support such notions. Htt has been implicated in the transport of lipid vesicles
(endocytic, synaptic

or

lysosomal),

especially along

microtubules

[104-107].

Approximately 50% of endogenous htt were found to partitions with membranes after
subcellular fractionation of neuron-like clonal striatal cells [108]. In vitro experiments
have shown that brain lipids large unilamellar vesicles (LUV) interacted with htt exon1
fragments and enhanced fibril formation of htt aggregates [109], highlighting the
importance of Nt17 in lipid/protein binding. Expanded polyQ-conferred nuclear
localization of htt appears to require additional htt sequences such as Nt17 [110], and Nt17
itself has been implicated to function as a nuclear export signal [111]. Htt also associates
with acidic phospholipids [112] which could play a role in nucleating aggregation.
Furthermore, htt localizes to brain membrane fractions [113] which are primarily
comprised of lipids.
There are a variety of membrane-associated functions attributable to htt in which
the lipid-binding properties of Nt17 may play a role. These functions include cellular
adhesion [114], motility [115, 116], cholesterol and energy homeostasis [117], and as a
molecular scaffold for coordination of membrane and cytoskeletal communication
[112] as well as facilitating microtubule-dependent vesicle transport [118]. Nt17 facilitates
the trafficking of htt exon 1 to membranes associated with the ER, autophagic vacuoles,
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mitochondria, and Golgi [39, 119]. Membrane curvature sensing, facilitated by AH
structural characteristics of Nt17, may play a mechanistic role in these functions [60].
Additional evidence that Nt17 directly interacts with lipid membranes was provided by the
observation that the binding of htt exon 1 to large unilamellar vesicles composed of
phosphatidylcholines (PC) or a mixture of PC and phosphatidylserines (PS) enhanced the
helical content of Nt17 [39]. These changes in helical content were blocked by changing
the eighth residue of Nt17 to a proline [39]. Through solid state nuclear magnetic
resonance structural analysis studies, Nt17 of htt has been found to have an amphipathic
alpha helical structure with membrane binding properties [120, 121], where it transition
structurally from random-coil in solution to an α-helical structure upon binding lipid
bilayers. Nt17 in synthetic polyQ peptides was required for synthetic polyQ peptides to
bind model brain lipid extract membranes [53]. Synthetic polyQ peptides with a variety
of flanking sequences readily form fibrils in solution or solid surfaces such as mica, but
lipid membranes stabilize discrete oligomeric aggregates of polyQ peptides that contain
Nt17 [53]. However, both Nt17 and a C-terminal polyP domain were required for polyQ
peptides to destabilize membrane structure, leading to leakage. Computational studies
further support the important role of Nt17 in htt/lipid interactions and also provide
evidence that the presence of both Nt17 and polyP enhance the interaction of htt with
bilayers [63]. The cooperative effect of Nt17 and the polyP domain in disrupting
membranes may be particularly important in light of observed interactions between these
two domains in a cellular environment that is altered with increasing polyQ length [122].
The binding and disruption of lipid membranes by full htt exon 1 constructs can be
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partially inhibited by the addition of N-terminal tags, further supporting a prominent role
of Nt17 in these phenomena [123].
In terms of a potential role in htt-related toxic mechanisms, the accumulation of
monomeric htt and/or prefibrillar aggregates directly binding lipid membranes has been
shown to disrupt bilayer integrity and to induce mechanical changes in the membrane
[123, 124]. Another factor regulating the interaction of htt with lipid membranes
mediated by Nt17 are the previously discussed PTMs, which are known to be involved in
htt translocating to specific organelles [39, 125]. Additional affinity-based components
for the interaction of other AHs with lipid bilayers also play a role, including
electrostatics [126, 127], partitioning of lipid components [128-130], or the presence of
other specific recognition motifs [131, 132]. The availability of Nt17 to interact with lipid
membranes could also play an important role in cell to cell transport of htt aggregates.
This may prove particularly important with the realization that there are non-cellautonomous toxic effects associated with HD [133-137]. The study of htt/lipid membrane
interaction may contribute to the understanding of the mechanism of pathology of HD.
1.5 Lipid Composition in huntingtin/lipid interaction
As previously discussed, htt is found highly associated with a variety of cellular
and subcellular membranes that are predominantly comprised of lipids, consisting of
physiological composition of cholesterol, sphingomyelin and ganglioside (GM1).
Cholesterol affects the functional properties of membrane-resident proteins (ion channels
and transmitter receptors), as well as plays a role in signal transduction, synaptogenesis,
and neurotransmitter release [138-140]. Abnormalities in cholesterol metabolism and
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homeostasis have been observed in cellular and animal models of HD, as well as in HD
patient tissues [141-143]. However, the specifics of altered cholesterol content associated
with HD remains controversial. It has also been demonstrated that reduced synthesis of a
gangliosides, GM1, occurs in the cells and brains of HD patients, leading to increased
programmed cell death. However, administration of GM1by continuous infusion into the
ventricles of brains of HD mice results in complete reversal of motor defects in these
mice [144], and increased in phosphorylation at Ser13 and Ser16 [90], suggesting that the
mechanism of GM1 neuroprotection could be phosphorylation of htt. While the
importance of htt aggregation in HD has long been appreciated, the impact of specific
lipid components, such as cholesterol, GM1 and sphingomyelin, on modulating htt
aggregation is poorly understood. The final part of this thesis involves evaluating how
exogenously GM1, sphingomyelin, added and cholesterol, affects htt/lipid membranes
interaction.

1.6 Dissertation Outline and Study Rationale
Although it has been over two decades since the discovery of the IT15 gene, great
strides have been made in understanding HD, but there is still no therapeutics that either
cures or stops disease progression. Based on this and the ongoing discussion on the role
of lipid membranes and posttranslational modification as potential modulators of htt
aggregation the following topics are addressed in this dissertation:
(1) A variety of protein motifs play a critical role in sensing and targeting specific
physical properties of membranes. Htt, in particular, interacts with a variety of
membranous structures within the cell, and Nt17 of htt is an AH lipid-binding
1.
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domain. AHs are also known to detect membrane curvature. Flat supported lipid
bilayers are commonly used as model membranes for AFM studies of protein
aggregation; however, these supported bilayers usually lack curvature. Chapters
2 and 3 addresses if htt exon1 preferentially binds curved membranes by
developing and validating a system of a model supported lipid bilayer with both
flat and curved regions. This system is exposed to a truncated htt peptide to
determine if curvature plays a role in the interaction of htt with lipid membranes.
(2) Nt17 influences the aggregation of N-terminal fragments of htt and their direct
interactions with lipid membranes. Furthermore, PTMs within Nt17 have a
profound effect on the toxicity associated with mutant htt containing expanded
polyQ domains. However, the impact of acetylation of Nt17 on modulating htt
aggregation and its interactions with lipid bilayers is poorly understood. Chapter
4 investigates the influence of acetylation of Nt17on htt aggregation on lipid
bilayers.
(3) Finally, the relevance of htt aggregation in HD has been studied extensively, and
lipids play important roles on the aggregation of a variety of htt fragments.
However, the role and impact of specific lipid components, such as cholesterol,
sphingomyelin and GM1, on modulating htt aggregation is not quite understood.
Abnormalities in cholesterol homeostasis having been implicated in HD, and
direct administration of GM1 into yeast artificial chromosome (YAC) mice
model expressing the full length mutant huntingtin was found to reduce
pathology. Chapter 5 sought to understand the role of these specific lipid
components on htt aggregation with the potential implications to HD.
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1.7 Atomic Force Microscopy
To address these questions, a number of techniques including, AFM were used to
study htt/lipid interaction. Htt forms a variety of nanoscale aggregates through a complex
pathway that involve oligomers, off-pathway aggregates and fibrils (as previously shown
in Fig. 1). Due to the complexity of the aggregation pathway and nanoscale size of these
aggregates, AFM has emerged as a robust and versatile tool for distinguishing and
characterizing the morphology of disease-related protein aggregates [145-147]. AFM can
be operated both in air and solution, allowing the dynamic tracking of aggregates under
near physiological conditions, at nanoscale resolution [29, 145, 148-152]. Since its
inception by Binning and Rohrer [153], AFM has become an invaluable tool for threedimensional imaging as well as measuring structural features of aggregates [124, 154].
As shown in Fig. 3, AFM measures the vertical displacement of a cantilever with an
ultra-sharp probe that interacts with the sample surfaces. A laser is reflected off the back
of the cantilever into a photosensitive photodiode detector. The tip is brought close to the
sample surface, and the interaction tip/sample forces cause the deflection of the
cantilever. This deflection is measured using an optical lever provided by reflecting a
laser off of the cantilever onto a photodiode. The piezo scanner enables the cantilever to
scan back and forth across the sample. Images are generated by raster scanning the tip
across the sample surface. The feedback loop helps maintain constant deflection or
amplitude while imaging.
There are three main modes of AFM, namely contact, tapping/intermittent, and
non-contact mode. In contact mode, commonly described as the most direct AFM mode,
the probe is brought in direct contact with the surface and the deflection of the cantilever
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Figure 3. Basic schematic illustration of an AFM. The ultra-sharp tip is brought in
close contact with the surface, causing the deflection of the cantilever. The defection is
measured by the photodiode, and together with the feedback loop and controller, threedimensional topographical images of surfaces with nanoscale resolution can be obtained

is monitored. This AFM mode allows for fast scanning and is good for imaging hard
samples. However, it is heavily influenced by frictional and adhesive forces [155], and as
such considerable amount of lateral and shear forces are generated, causing damage to
soft , biological samples [156] .
In noncontact AFM, the probe does not “touch” the surface but it oscillates above
the surface during scanning. As the tip approaches the surface, the forces between the tip
and the surface (as shown in Fig. 3) change the amplitude of the cantilever’s resonant
vibration. In tapping mode, the cantilever is harmonically oscillated near its resonance
frequency, ωο, by a piezoelectric bimorph element mounted near the cantilever root. The
probe tip is placed in close proximity to the sample surface and allowed to intermittently
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contact the sample, leading to a decrease of the cantilever oscillation amplitude from the
“free” amplitude, Ao, to a tapping amplitude, A [157, 158]. Owing to its ability to
minimize potential damage to delicate, biological samples, tapping mode AFM was used
for the studies presented in this dissertation.
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2. Scanning probe acceleration microscope and the development of supported lipid
bilayers with curvature1,2

Abstract
Tapping mode atomic force microscopy (TMAFM) has become a useful method
to obtain physical insights into the formation of toxic protein aggregates associated with
amyloid diseases on membranes. However, recent advances in reconstructing the timeresolved tip/sample force during the imaging process have provided access to information
relating to the mechanical properties of these surfaces. The ability to directly image and
measure changes in mechanical properties of lipid bilayers associated with exposure to
amyloid-forming peptides in a “quasi” real-time fashion can provide new insights that are
exceedingly difficult to obtain using other traditional methods. However, the absence of
membrane curvature, which can heavily influence the interaction of proteins at lipid
interfaces, is one of the several limitations associated with using flat, supported bilayers
as model surfaces. I, therefore, developed model lipid bilayer systems in which the
underlying solid support is comprised of flat and curved regions to induce regions of
curvature in the bilayer. To accomplish this, 50 nm silica nanoparticles were deposited on
a silicon substrate coated with poly-L-lysine. This substrate was exposed to total brain
lipid extract (TBLE) vesicles, which can fuse on surfaces to form lipid bilayers. Using an
AFM based, force reconstruction technique; scanning probe acceleration microscopy
This chapter is based on the works:
1
Recovering Time-Resolved Imaging Forces in Solution by Scanning Probe Acceleration Microscopy:
Theory and Application in Surface Science Tools for Nanomaterials Characterization.
2
Curvature enhances binding and aggregation of huntingtin at lipid membranes.
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(SPAM), to measure changes in the mechanical properties of the lipid bilayers, the
formation of supported bilayer on the surface that contained flat and curved regions was
confirmed. This chapter gives a detailed description of the principles of the SPAM
technique, and its application in developing supported lipid bilayers with curvature.

2.1 Introduction
TMAFM, [1] a widely used dynamic scanning probe technique, obtains
topography images of surfaces by monitoring the oscillation amplitude of a cantilever
integrated with an ultrasharp probe tip. In this imaging mode, the cantilever is commonly
driven near its resonance frequency, ωο, by a piezoelectric bimorph element mounted
near the cantilever root. The probe tip is placed in close proximity to the sample surface
and allowed to intermittently contact the sample, leading to a decrease of the cantilever
oscillation amplitude from the “free” amplitude, Ao, to a tapping amplitude, A [2, 3]. For
rigid surfaces, the cantilever oscillation amplitude decreases linearly as the distance
between the tip and the sample, Do, becomes smaller. As a result, surface topography is
mapped by raster scanning the probe across the surface while using a feedback loop to
continuously adjust the vertical (in the z direction) extension of a piezoelectric scanner to
maintain a constant tapping amplitude or set-point ratio, s = A/Ao.
There is significant interest in using TMAFM to simultaneously map topography
and mechanical properties of surfaces and a variety of methods have been developed
toward achieving this goal. While monitoring the phase of the cantilever in tapping mode
is a common method to acquire some insight into the mechanical properties of surfaces,
[4, 5] such images can be difficult to interpret due to various causes of energy dissipation,
including capillary forces, [6] viscoelasticity of the sample, [7] cross talk with
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topography, [8] and frictional forces associated with the tilt of the cantilever and/or
surface [9]. Furthermore, the phase behavior of the cantilever becomes increasingly
complicated when imaging in solution. For example, it has been demonstrated that the
phase contrast associated with soft cantilevers imaging in solution can arise from either
(i) energy propagation during the tapping event that excites higher eigenmodes of the
cantilever mediated by conservative short-range interactions, or (ii) tip/sample energy
dissipation [10].
A more straight-forward way to gain insight into sample mechanics is by
obtaining the time-resolved force interaction between the surface and the tip during
standard TMAFM operation. The first successful reconstruction of time-resolved
tip/sample forces in a TMAFM experiment was accomplished by taking the inverse
Fourier transform of the Fourier-transformed cantilever trajectory divided by its transfer
function [11]. Since then, a variety of other methods have been developed that are
capable of obtaining time-resolved tip/sample forces and construct images based on these
forces [12-19].
There are several experimental advantages to using tapping forces as a method to
map mechanical properties of surfaces. Due to their basis in the tapping mode, such
methods offer high spatial resolution and are relatively nondestructive. Other traditional
AFM techniques used to measure and/or map mechanical properties of surfaces (i.e.,
force volume imaging and nanoindentation) often require large deformation of soft
samples, leading to decreased spatial resolution and possibly irreversible sample damage,
whereas tapping mode forces are adaptive to changes in surfaces properties. As scan rates
used for simple tapping mode AFM imaging are typically much faster than other methods
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Figure 1. SPAM is a method for reconstructing the time-resolved tip/sample forces
associated with TMAFM imaging in solution. In this example, (a) a mica substrate
with small supported lipid bilayer patch is imaged to acquire the surface topography
while the entire cantilever deflection signal is captured. (b) The deflection trajectory of
the cantilever is filtered using a "comb-filter" based on Fourier transforms, and the
second derivative of the trajectory is used to reconstruct the tip/sample forces. (c)
Images are constructed based on specific features of the tip/sample force, such as the
maximum tapping force, which can be related to surface mechanical properties.

, the mapping of surface properties can be accomplished in a timelier manner. This,
perhaps, could provide the ability to probe dynamic changes in a surface's mechanical
properties in response to some external stimulus or environmental change.
The laboratory of Dr. Tomasz Kowalewski at Carnegie Mellon University,
developed a method to recover the time-resolved tip/sample force in TMAFM while
operated in aqueous solution is scanning probe acceleration microscopy (SPAM) (Fig. 1)
[14]. The underlying principle behind SPAM is that the cantilever in TMAFM acts as an
accelerometer, which can be used to extract tip-sample forces during standard tapping
mode operation by calculating the second derivative of the cantilever deflection signal.
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Real deflection signals from TMAFM experiments contain noise that is amplified by this
analysis. As the signal to noise ratio in most commercially available AFMs would
overcome the ability to reconstruct the tapping force by this simple method, a means to
filter these signals is crucial if SPAM is to be useful experimentally. This problem is
solved by taking advantage of the fact that most of the information about the deflection
trajectory and the tapping event is contained in higher harmonic frequencies associated
with the drive, [11, 20, 21] making it possible to filter the signal by ‘‘comb’’ filtering,
i.e., by taking its Fourier transform and inverting it while selectively retaining only the
intensities at integer harmonic frequencies of the drive. Such a comb filtering method
works particularly well in fluid TMAFM because of the highly distorted character of the
deflection signal [22-24].

2.2 Numerical model of the entire imaging process of TMAFM in solution
To get a complete understanding of the tip/sample interaction associated with
TMAFM, numeric simulations are often performed in which the cantilever is modeled as
a driven damped harmonic oscillator [25], where

𝐹𝑒𝑥𝑡 = 𝑚𝑒𝑓𝑓 𝑧̈ + 𝑏𝑧̇ + 𝑘[𝑧 − 𝐷𝑜 + 𝑎𝑜 sin(𝜔𝑡)]

(1)

meff is the effective mass of a cantilever, b is the damping coefficient, k is the cantilever
spring constant, z is the position of the cantilever with respect to the surface, D0 is the
resting position of the cantilever base, a0 is the drive oscillation amplitude, ω is the drive
frequency, t is the time, and Fext is the tip/sample force.
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Figure 2. Comparison of simulated cantilever position and deflection trajectories
in high Q and low Q systems. Simulations with high Q systems are applicable to
TMAFM in air; there is minimal difference between the position and deflection
trajectories. In low Q systems, which are associated with TMAFM imaging in solution,
there are distinct differences between the position and deflection trajectories

Although cantilever position, z, is often monitored in AFM simulations, in real
experiments, most microscopes monitor the amplitude of the cantilever deflection, y,
which is simply related to the position by:

𝑦 = 𝑧 − 𝐷𝑜 + 𝑎𝑜 sin(𝜔𝑡).

(2)

TMAFM can be operated in air or in fluids, and their major differences is in the quality
factor (Q) of the cantilever, [23, 26] described by the following relationship

𝑄=

𝐴𝑜⁄
𝑎𝑜

(3)

where Ao is the free cantilever oscillation amplitude. In short, Q is the ratio of the energy
stored in a system divided by the energy loss per cycle, and is typically in the range of ~
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200–400 in air, whereas in fluids it is only ∼1–5. This lower Q is primarily due to the
large hydrodynamic damping associated with oscillating the cantilever in fluids. In high
Q systems, the free cantilever oscillation amplitude is significantly larger than the drive
oscillation amplitude. When operating TMAFM in a low Q system, the cantilever
deflection and position trajectories differ significantly during tapping events as the drive
amplitude is comparable to the free amplitude. As a result, a characteristic anharmonic
distortion is produced in the deflection trajectory as the cantilever tip contacts the sample
surface (Fig. 2b). As a result, tin modeling TMAFM in solution, it is necessary to rewrite
the cantilever motion in terms of deflection as

𝐹𝑒𝑥𝑡 = 𝑚𝑒𝑓𝑓 [𝑦̈ − 𝑎𝑜 𝜔2 sin(𝜔𝑡)] + 𝑏[𝑦 + 𝑎𝑜 𝜔 cos(𝜔𝑡)] + 𝑘𝑦

(4)

It should be noted there are several sources of distortion in cantilever deflection signals in
experimental systems, including nonlinearities of the detector and electronics of the AFM
that may need to be accounted for when comparing numerical simulations to
experimental results.
In TMAFM the cantilever oscillation continuously changes the separation
distance between the probe tip and the surface, allowing the tip to intermittently contact
the sample during each oscillation cycle. Thus, there are two tip/sample interaction
regimes required for modeling the time-resolved imaging force: (a) when the cantilever
tip and sample surface are not in contact and (b) when the tip and surface make contact
during the tapping event. For scenario (a), the separation distance between the cantilever
tip and the sample surface, z, is greater than the interatomic distance, aDMT, and during the
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contact portion (b), z is equal to or smaller than aDMT. For scenario (a) the force can be
described by the Derjaguin-Landau-Verway-Overbeek (DLVO) theory; [27] however,
because most biological experiments are performed under near physiological conditions
in a saline buffer, the force associated with the electric double layer effect is negligible,
resulting in a short Debye length [28]. Thus for simplicity, the non-contact force can be
approximated using the van der Waals interaction between a sphere (the cantilever tip)
and a flat surface [27]

𝐹𝑒𝑥𝑡 = −

𝐻𝑅𝑡𝑖𝑝
6𝑧 2

𝑓𝑜𝑟 𝑧 > 𝑎𝐷𝑀𝑇

(5)

where H is the Hamaker constant and Rtip is the tip radius [29]. For scenario (b), the
tip/sample force interaction can be described using a Derjaguin-Muller-Toporov (DMT)
potential,

𝐹𝑒𝑥𝑡 =

4
3𝜅𝑒𝑓𝑓

√𝑅𝑡𝑖𝑝 (𝑎𝐷𝑀𝑇 − 𝑧)

3⁄
2

−

𝐻𝑅𝑡𝑖𝑝
2
6𝑎𝐷𝑀𝑇

𝑓𝑜𝑟 𝑧 ≤ 𝑎𝐷𝑀𝑇

(6)

where
𝜅𝑒𝑓𝑓 =

2
1− 𝜈𝑡𝑖𝑝

𝜋𝐸𝑡𝑖𝑝

+

2
1− 𝜈𝑠𝑎𝑚𝑝𝑙𝑒

𝜋𝐸𝑠𝑎𝑚𝑝𝑙𝑒

(7)

where E is the Young's modulus and ν is the Poisson coefficient of the tip or sample.
In addition, a feedback loop equipped with an integral gain can be incorporated
into this numerical model to simulate the entire TMAFM imaging process.
Implementation of a feedback loop can be accomplished by systematically determining
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the cantilever amplitude for each oscillation cycle, direct comparison of this amplitude to
a predetermined set-point amplitude, and adjusting the tip/surface separation distance to
maintain the set-point amplitude. In this way, a simulated trace of the surface, which is
simply the required correction in tip/surface separation distance, can be obtained for
different model surface topographies. Combined with the ability to change the values of
the Hamaker constant and/or surface Young’s modulus, simulations of imaging a wide
array of surfaces with TMAFM can be performed to fully understand how the timeresolved tip/sample force responds to surface properties.

2.3 Basic principles underlying SPAM
Equation 4 above can be rearranged to show that that the acceleration of the
cantilever is directly related to the tip/sample force scaled by the effective mass of the
cantilever.

𝑦̈ =

1
𝑚𝑒𝑓𝑓

[𝐹𝑒𝑥𝑡 − 𝑏𝑦̇ − 𝑘𝑦 + 𝑚𝑒𝑓𝑓 𝜔2 𝑎𝑜 sin(𝜔𝑡) − 𝑏𝑎𝑜 𝜔 cos(𝜔𝑡)].

(8)

This suggests that by taking the second derivative of the measured deflection signal the
time-resolved tip/sample force can be recovered. In its simplest form, this process
amounts to treating the cantilever as a local accelerometer that can be raster scanned
across a surface. In this way, topographic and tip/sample force information can be
obtained in one experiment simultaneously. This is the basis for SPAM. The last four
terms of Equation 8 are all related to the action of driving the cantilever, and as a result,
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oscillate at the drive frequency. This allows these extraneous terms to be easily
distinguished from the tip/sample force, or even filtered out.
As previously mentioned, real cantilever deflection trajectories contain noise. The
deflection trajectory of the cantilever can be filtered using a Fourier transform based
harmonic comb filter. In this process, a sliding window Fourier transform is performed
on the cantilever deflection signal, only intensities in the resulting power spectrum
corresponding to integer harmonic frequencies of the drive are kept, and these are used to
reconstruct a deflection signal, yrec(t), by an inverse Fourier transform based on the
equation

𝑦𝑟𝑒𝑐 (𝑡) = 𝑓̂ −1 [𝑦(𝜔) ∑𝑁
𝑘=1 𝛿(𝜔 − 𝑘𝑤𝑜𝑝𝑒𝑟 )]

(9)

where δ is Dirac's delta function, ωoper is the operating frequency, and N is the highest
harmonic distinguishable about the noise level. The effectiveness of the use of the comb
filter to accurately reconstruct the deflection trajectory requires a sufficient number of
harmonics, typically more than 18, to be above the noise level in the power spectrum. As
previously mentioned, TMAFM in fluids is characterized by a distinct distortion in the
cantilever deflection trajectory associated with the tapping event, [23, 24, 26] and this
distortion inherent in fluid TMAFM results in an adequate number of higher harmonics
above the noise to facilitate comb filtering and reconstruction of the tip/sample tapping
force from the second derivative (or acceleration) of the cantilever deflection signal. The
sliding window of this filter typically contains 5-10 oscillation cycles, and the window is
advanced one oscillation cycle at a time to maintain local information about the
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tip/sample interaction. Nonetheless, with this ability to filter cantilever deflection
trajectories, spatially resolved force maps can be constructed based on the second
derivative. The extraneous terms in Equation 8 can be suppressed from the reconstructed
force by excluding the fundamental frequency, i.e. drive frequency, from the inverse
Fourier transform; however, excluding this frequency diminishes the accuracy of the
recovered force by reducing its magnitude. The reconstructed trajectory obtained from
the comb filter also loses information contained in harmonics below the noise level.
Furthermore, it should be noted that the harmonic comb filter should only be applied to
periodic motion of the kind commonly observed in TMAFM and is not applicable to
motion exhibiting period doubling or aperiodic/chaotic character. .

2.4 Features of the time-resolved tip/sample force are independent of surface
topography
TMAFM can be used to image a wide variety of sample surfaces, with a range of
topographical features. In TMAFM experiments, surface features may vary in height
from sub-nanometer to several micrometers. To compare tapping mode imaging forces to
mapping mechanical properties of surfaces, the features of the time-resolved tip/sample
tapping force must be independent of the surface topography.
To determine the role of surface topography on tip/sample tapping forces, simulations of
complete TMAFM experiments can be performed to understand the impact of a variety of
model surfaces with distinct morphologies on imaging forces (Fig. 3). Here, three model
surfaces are presented: 1) a region with increased RMS roughness, 2) a flat step, and 3) a
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Figure 3. Simulations to determine the effect of surface topography on tip/sample
imaging forces. A variety of surface topographies were modeled: (a) a rough surface,
(b) a flat step, and (c) a curved feature where roughness or height was varied from 1-5
nm. The maximum and minimum tapping forces, (d-f) and (g-i) respectively, were
averaged over the altered surface topography and found to be independent of changes
in surface topography.

round feature. These model surfaces represent a large number of the potential
topographies that may be encountered in real AFM experiments. There are two features
of the tapping force that are of interest here: (1) the maximum tapping force, Fmax,
defined as the most positive force experienced between the cantilever tip and the sample
surface during each cantilever oscillation cycle, and (2) the minimum tapping force, Fmin,
defined as the most negative force experienced between the cantilever tip and the sample
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surface. The size of these features can be systematically increased to determine changes
in Fmax and Fmin associated with imaging these model surfaces. All other surface
characteristics (such as Young's modulus, Hamaker constant, etc.) and imaging
parameters (set-point ratio, free amplitude, cantilever spring constant, etc.) were held
constant in these simulations. Importantly, the average Fmax and Fmin associated with
imaging all three of these surfaces do not change as a function of the size of the feature in
the model, as long as the feedback loop is able to maintain proper tracking of the surface.
Fmax for the various topographies were averaged over the altered surface feature (the
rough patch, the step, or the round feature) and had an approximate value of 25 nN for
each type of surface and each height variation (Fig. 3d-f). The Fmin for each surface
variation was approximately -2 nN, which was exactly the same as the flat region of the
surface. This indicates that as long as the feedback loop is optimized, changes in the
time-resolved tapping forces are independent of topographical features.

2.5 Application of SPAM
Most studies utilizing SPAM have focused on supported lipid membranes as well
as a variety of systems. Supported bilayers have a considerably lower elastic modulus
compared commonly used surfaces such as mica and silicon, so this system provides a
surface with a soft region (supported bilayer) and hard region (exposed mica).
Histograms of Fmax and Fmin associated with imaging this system are distinctly bimodal,
with each mode corresponding to either the mica or bilayer portions of surface, and
providing excellent contrast in the reconstructed force images (Fig 4b-c). Consistent with
the simulation results, the values of Fmax corresponding to the bilayer were lower in
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Figure 4. SPAM imaging of a supported lipid bilayer patch on mica. (a)
Topography image with the green line corresponding the height profile to the left. (b)
Fmax and (c) Fmin images are presented with histograms of these respective forces for
every tapping event presented to the left of the images. The insets zoom in on small
areas containing small, stacked bilayer on the patch (blue arrows).

comparison with those corresponding to mica. The magnitude of Fmin associated with
imaging mica was larger than that for the bilayer patch, indicating that the tip adhered
more strongly to the mica surface. Several studies have measured mechanical changes in
supported lipid membranes using SPAM. For example, SPAM has been used to
determine the effect of cholesterol on the modulus of lipid bilayers [30], how exposure to
lipoprotein particles alter membrane mechanics, [31] and how membrane disruption
caused by a variety amyloid-forming proteins alter local mechanical properties of lipid
bilayers [32-35]. In this chapter, SPAM was used to monitor changes in the mechanical
properties during the formation of supported lipid bilayers with membrane curvature.
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2.6 SPAM in the developed of supported lipid bilayers with curvature
Supported lipid bilayer patches on mica substrate represented the first successful
application of the SPAM technique on an experimental system. These bilayers have a
considerably lower elastic modulus compared to mica, so this system provides a surface
with a soft region (supported bilayer) and hard region (exposed mica). Supported lipid
bilayers are commonly used as model membranes for AFM studies of protein
aggregation. However, these supported bilayers usually lack curvature. By forming a
bilayer on top of silica nanobeads (50±10 nm) deposited on a silicon substrate, model
supported lipid bilayers with flat and curved regions were developed for AFM studies
(Fig. 5). The presence of the bilayer over the beads was validated by continual imaging of
the formation of the bilayer, height measurements, and spatially resolved mechanical
measurements of the resulting bilayer using SPAM. Interpretation of this data was
facilitated by numerical simulations of the entire imaging process.

2.6.1 Preparation of total brain lipid extract
Lyophilized total brain lipid extract (TBLE) (Avanti Polar Lipids) was dissolved
in chloroform (ACROS Organics). The chloroform was evaporated using a Vacufuge
plus (Eppendorf) to form a thin lipid film on the bottom walls of a micro centrifuge tube.
The TBLE was reconstituted in 10 mM Tris HCl buffer (pH 7.3) with periodic vortexing
to a concentration of 1mg/ml. To facilitate bilayer and multilayer sheet formation, the
lipid sample tube went through five freeze/thaw cycles by sequential immersion in liquid
nitrogen followed by thawing at 37 oC in a thermomixer (Eppendorf) [36]. The lipid
sample was then bath sonicated for 45 minutes to facilitate vesicle formation. Using the
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hanging drop method, 15µl of 1:1 mixture of TBLE/Tris-HCl was added directly into an
AFM fluid cell on a clean silicon substrate decorated with 50 nm silica nanoparticles
(Polysciences, PA). The same lot of lipids was used in all experiments.

2.6.2 Preparation of poly-L-lysine coated silicon substrate
Ultra-flat silicon wafers, type<100> (Ted Pella) were cut into 1cm x 1cm square
sizes, and sequentially sonicated in acetone, absolute ethanol, and deionized water for 20
minutes each. The wafers were then kept under water overnight and dried by blowing
canned air. The clean substrates were placed under ozone for 1 hour to remove any traces
of organic contaminants [37] from the acetone and ethanol. Once more, the wafers were
rinsed in ultrapure water, dried with air, and placed on a hot plate at 30 oC to remove any
residual solvent present. These substrates were stored in a dust free petri dish prior to use.
A 25µl aliquot of 0.1% poly-L-lysine was evenly spread on the clean, square silicon
substrate and placed on a hot plate at 30oC for 5 minutes, followed by rinsing with 1 ml
of deionized water to remove excess unbounded poly-L-lysine molecules [38].

2.6.3 Nanoparticles deposition on silicon substrate
Silica nanoparticles purchased from Polysciences were diluted to the desired
concentration of 0.010% (0.10g/L) with ultrapure water, followed by 1 hour of sonication
prior to deposition. A 20 µl drop of silica dispersion was evenly spread on the silicon
substrate and allowed to slowly dry at room temperature [39]. This was rinsed with 100
µl of ultrapure water to remove any excess, loosely bound beads on the surface followed
by air drying, and stored in a dust free environment prior to AFM experiments.
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2.6.4 In situ AFM and SPAM imaging conditions
A Nanoscope V Multimode AFM (Veeco,Santa Barbara,CA) equipped with a
tapping mode fluid cell and an O ring was used to perform in situ AFM experiments. The
silicon substrates with beads were scanned using a rectangular shaped silicon nitride
cantilevers (Vista probes) with a nominal spring constant of 0.1 N/m. Typical scan rates
ranged from 1-2 Hz, and drive frequencies of 5 - 6 kHz were used. For scanning probe
acceleration microscopy (SPAM) analysis,[40] topography images were captured at
512x128 pixel resolution. While the topography images were being captured, the
cantilever deflection trajectories were simultaneously captured with a signal access
module (Veeco) and CompuScope 14100 data acquisition card (Gage, Lachine, QC) at
2.5 MS/s and 14 bit resolution with a range of 2 V. The captured cantilever trajectories
were filtered with a sliding-window Fourier transform-based harmonic comb filter, and
the second derivatives of the filtered cantilever deflection trajectories were taken and
multiplied by the effective mass, meff, of the cantilever to obtain the time-resolved-based
tapping force between the tip and sample. To understand the tip/sample forces, we carried
out numerical simulations in which the cantilever was modeled as a driven damped
harmonic oscillator as previously described.
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2.7 Results
2.7.1 Development of a system containing supported curved and flat lipid bilayers.

Figure 5. Time-lapse AFM images taken in solution of a TBLE bilayer forming
over silica beads immobilized on silicon. Images were taken of the surface (a) before
exposure to lipid vesicles and (b−d) at 30 min increments after injection of lipid
vesicles. The blue arrow in panel (a) indicates a silica bead that was knocked off of the
surface by the imaging process and does not appear in subsequent images. The red
arrow in panel c indicates a lipid vesicle that did not completely flattened and fused
into the bilayer. A zoomed-in AFM image was taken at (e) 30 min after injection of
TBLE into the fluid cell with the black line corresponding to the (f) height profile. (g)
Histogram of height measurements associated with each pixel in the image presented in
panel e demonstrating the height of the bilayer.
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To provide a substrate capable of inducing well-defined, local regions of
curvature in a supported bilayer, the strategy of using silica beads (diameter of 50 ± 10
nm) that were immobilized on clean silicon surfaces pre-treated with 0.1% poly-L-lysine
as substrates was employed. These substrates were subsequently exposed to vesicles
comprised of TBLE, resulting in the formation of a lipid bilayer on the surface via the
process of vesicles flattening and fusing on the surface (Fig. 5b-c). This strategy would
provide both curved and flat bilayers in the same system, and would allow for the direct
tracking of htt aggregation on these two distinct regions by AFM imaging in solution.
While the beads were found to be firmly attached to the surface, the process of acquiring
AFM images and/or injecting solutions containing vesicle into the fluid cell did result in
rare instances where a bead was displaced from the surface (Fig. 5a, blue arrow). The
formation of the lipid bilayer on the flat portions of the substrate could be tracked by
continuous AFM imaging of the scan area, and smooth bilayer completely covered these
flat regions of the surface typically within ~90 minutes. At intermediate time points, the
thickness of the bilayer could be determined from analysis of AFM height images. The
supported bilayer above the flat silicon substrate was 7.3 ± 0.4 nm, as demonstrated by
height profiles and histograms of the height associated with every pixel in the image (Fig.
5e-g).
Despite the obvious formation of lipid bilayer on the flat portions of the substrate,
there are two primary ways the bilayer can form to accommodate the presence of the
immobilized bead: 1) by forming a pore around the periphery of the bead or 2) by
forming a bilayer over the top of the bead, thus enveloping it (Fig. 6). Both scenarios
have been observed in the literature [39]. The first scenario is not useful for this study, as
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Figure 6. Schematics demonstrating two potential ways the lipid bilayer could be
arranged with respect to the beads: (a) the bilayer could form along the surface but
not over the bead or (b) the bilayer could form over the top of the bead, which would
result in different packing associated with the forced geometry (insets).
it would not result in a curved model bilayer; however, the second scenario would
provide such a surface. As a result, the formation of the bilayer forming over the top of
the beads, thus encapsulating them, needed to be verified. Previous studies used
comparison of the height of the bead and phase imaging before and after addition of lipid
to determine of the bilayer formed over the bead [39]. The logic behind this approach is
that if the bilayer forms on the flat substrate and on top of the bead that there would be no
apparent change in height of the bead. If the bilayer formed a pore around the bead, than
the observed bead height would be decreased by the thickness of the bilayer. Therefore,
the average height of the exact same beads immobilized on the silicon surface were
compared before addition of any lipid and after the bilayer appeared to have completely
covered the flat portions of the substrate. There was an observed decrease of 2.9 nm in
the average bead height associated with the presence of the lipid bilayer. As the bilayer
on the flat region was known to have an average height of 7.3 nm, this smaller observed
height suggests that some form of lipid did indeed deposit over the top of the beads, but
that there is also something physically different between the lipid on top of the bead and
the flat portion of the substrate.
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2.7.2 Validating bilayer formation on beads using imaging forces.
Analysis of the time-resolved imaging forces associated with tapping mode AFM
was performed in order to provide an understanding of why this small height different
was observed and providing further validation that bilayer had indeed formed over the
top of the bead. These imaging forces have been demonstrated to be highly dependent on
surface mechanical properties, and in particular, the maximum tapping force (Fmax),
defined as the peak or largest force occurring between the tip and surface during a single
tapping event, can be used as an indirect measure of the compression or Young's modulus
of a sample. While AFM topography images were obtained of the beads on silicon before
and after the formation of a lipid bilayer, the entire cantilever deflection signal was
captured and processed to recover the time-resolved tip/sample tapping force by SPAM.
In this way, the tapping forces can be associated with specific features in the topography
image and used to make surface maps of mechanical properties. To aid in interpreting
these force maps and directly relating them to the observed height measurements of the
beads, several numerical simulations of the complete tapping mode AFM imaging
process in solution were performed [33, 36, 41].

The rigidity of a surface can be modeled by varying the Young's modulus of the
sample in equation 7. A series of simulations were run with Young's modulus values of
the model surface ranging from 0.5 to 100 GPa (Fig. 7). All other imaging parameters
were held constant, e.g., cantilever free amplitude, spring constant, and set-point ratio,
when imaging these model surfaces. As a result, the total tip/sample imaging force over
an entire cantilever oscillation cycle was constant; however, this force was distributed
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Figure 7. Tapping mode AFM simulations demonstrate the relationship between
imaging forces and surface mechanical properties. (a) Simulated time-resolved
tip/sample forces associated with tapping mode AFM imaging on surfaces with
various values of Young’s modulus. (b) Maximum tapping force as a function of the
surface Young’s modulus for cantilevers with different spring constants.

differently over the entire tapping event (Fig. 7a). As the surface became increasingly
more compliant, the contact time between the tip and surface increases, resulting in the
imaging force being distributed over this longer contact time with a corresponding
decrease in the Fmax associated with the tapping event. This decrease in Fmax with smaller
values of surface Young's modulus followed a power law dependence (Fig. 7b). For any
given set of imaging parameters, this power law dependence between Fmax and the
surface Young's modulus was observed; although, the magnitude of the forces would
vary. For example, increasing the cantilever spring constant resulted in larger values of
Fmax , but for any given spring constant, the power law dependence between Fmax and
Young's modulus was observed (Fig. 7b). This demonstrates that for any given set of
imaging parameters that Fmax can be used as a way to compare the relative rigidity of
features within an AFM image.
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Figure 8. Tapping mode AFM simulations demonstrate the effect of Young's
modulus on the measured height of a 50 nm bead. (a) The model surface used in
these simulations consisted of a 125 nm long surface that contained 50 nm bead (radius
of 25 nm). (b) Comparison of Fmax associated with flat and curved substrates of the
same Young's modulus. (c) Simulated height traces of a bead with different values of
Young's modulus sitting on a substrate with a Young's modulus of 100 GPa. (d)
Simulated height traces of a bead with different values of Young's modulus sitting on a
substrate with a Young's modulus of 1 GPa. In both (c) and (d), the location of the bead
is highlighted with gray shading and the true bead height is indicated by the dashed
line.

Next, numerical simulations of imaging a bead deposited on a surface via tapping
mode AFM in solution were performed. The model surface used in these simulations was
125 nm long, and contained a 50 nm wide curved region that was 50 nm in height and
flanked by flat regions (Fig. 8a). The Young's modulus of the flat and curved regions of
the model surface could be independently altered. First, simulations were performed to
determine if changes in Fmax could potentially be associated with the curvature associated
with the beads. When the Young's modulus of the flat and curved regions of the model
surface was equal, there was no observed change in Fmax (Fig. 8b). When the Young's
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Figure 9. Maximum forces associated with imaging the surfaces confirm the
presence of lipid bilayers covering the beads. Height and the corresponding Fmax
images of beads deposited on silicon substrates (a) before addition of lipid vesicles, and
(b) after the formation of a lipid bilayer are presented.

modulus differed between the flat and curved regions, Fmax changed as would be
predicted based on the power law dependence, that is, the softer region was always
associated with a smaller Fmax regardless if this corresponded to the flat or curved region
of the surface. Next, the measured height of the model bead with varying values of
Young's modulus (ranging from 0.5 GPa to 100 GPa) with respect to the flat region of the
surface, which had a Young's modulus of 100 GPa (Fig. 8c) or 1.0 GPa (Fig. 8d), was
determined. When the bead and flat regions of the model surface had the same Young's
modulus, the measured height of the bead was the same as the true height of the bead, i.e.
50 nm. Whenever the flat region of the model surface was more rigid compared to the
bead, the observed height was smaller compared to the true height of the bead with the
observed height becoming increasingly smaller with lower values of Young's modulus. If
the flat portion of the surface was softer than the bead, the observed height of the bead
became systematically larger than the true height as the Young's modulus of the bead
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increased. The deviation of the height of the bead from the true height is a result of the
applied force associated with the imaging process compressing the softer regions of the
surface to a greater extent, which forms the basis of compliance based contrast in AFM.
Keeping the results of the AFM simulations in mind and to confirm the presence of a
lipid bilayer on top of the beads, the relative local rigidity of actual surfaces was mapped
before and after the formation of the lipid bilayer. This was accomplished by
reconstructing the time-resolved tip/sample force associated with every tapping event
while obtaining AFM images by SPAM, allowing Fmax (and thus rigidity) to be correlated
to specific regions of the surface. There was stark contrast in the Fmax image between
beads and bare silicon (Fig. 9). The magnitude of the force indicated that the beads were
softer compared to the bare substrate, which is consistent with the literature values of
Young's modulus for the two materials. The bulk Young's modulus of silica is ~ 73 GPa,
and the Young's modulus of silicon is typically >100 GPa. After a bilayer was observed
to completely form on the flat portion of the substrate, the magnitude of Fmax
corresponding to the location of the beads was smaller than the surrounding bilayer. As
supported lipid bilayers have a Young's modulus on the order of 1 GPa or smaller, the
Fmax associated with an exposed silica bead would be larger. Thus, observed Fmax
suggests that a lipid bilayer covered the beads and that the curved bilayers on top of
beads were more compliant (smaller Young's modulus) than the flat supported bilayers.
Based on the simulations, the increased compliance would result in a smaller measured
height of the bead as the tip compresses the curved bilayer to a larger extent compared to
the flat bilayer. The reduced Young's modulus of bilayers on top of the beads was most
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likely due to altered packing of the lipid components due to the induced curvature (Fig.
6b insets).

2.8 Discussion
While tapping mode AFM in solution is widely used to study morphological and
mechanical properties of supported lipid bilayers, one of the limitations associated with
comparing these results to physiologically relevant membranes is the lack of membrane
curvature associated with such systems. A potential method to induce curvature in
supported lipid membranes is introducing local curvature in the substrate. This was
accomplished by depositing silica nanobeads onto a silicon substrate, and by the process
of vesicle fusion, formed a supported lipid bilayer that covered the flat silicon substrate
and curved beads. Verification of the lipid bilayer forming on top of the beads was
provided by a combination of height measurements and analysis of time-resolved
tip/sample forces. Interpretation of both height and force analysis was aided by numerical
simulations of the entire imaging process involving a model surface of the correct
topography. Interestingly, Fmax revealed that not only did lipid organize on top of the
beads, but that bilayers on top of the beads had a qualitative reduction in the Young's
modulus compared to bilayer supported by flat regions of the substrate, which was
consistent with alterations in lipid packing associated with induced curvature [42, 43].
Collectively, these results demonstrate that membrane curvature can significantly alter
bilayer mechanical properties and that these changes can be detected by AFM tip/sample
force reconstruction.
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With the validation that supported lipid bilayers formed over the beads, a model
system that allowed studies to simultaneously monitor the interaction of proteins with
curved or flat regions of a bilayer was developed. There are several advantages associated
with such an approach. Mechanical measurements confirmed that the bilayer on top of
the beads was mechanically, and thus structurally, different compared with the flat
portions of the bilayer, and this is one of the advantages of using AFM for these types of
studies. Though, TBLE was used as the lipid system, this approach should be amenable
to various lipid systems as well. Due to the uniform size of the beads, the curved portions
of the supported bilayer are relatively uniform. In theory, the curvature can be modified
by changing the size of the beads; however, encapsulation of immobilized beads by a
lipid bilayer does not occur on all bead sizes, as has been previously observed [39, 44].
This reinforces the importance of confirming the formation of the bilayer over the top of
the beads, and lack of such confirmation is the main reason beads of varying size were
not used for the studies presented here. Another caveat associated with this approach that
should be noted is that these bilayers are still supported, and underlying substrates may
influence the fluidity and other properties of lipid membranes.

2.9 Conclusions
In conclusion, supported lipid bilayers with curvature may fight useful
applications, and such can be exposed to amyloid-forming proteins to determine the
impact of membrane curvature on protein/lipid interactions associated with diseases. It
can also provide indispensable information on nanobeads-lipid membrane interaction,
and cytotoxicity.
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3. Curvature enhances binding and aggregation of huntingtin at lipid membranes 1

Huntington disease (HD) is a genetic, autosomal neurodegenerative disease caused by an
expanded polyglutamine (polyQ) in the first exon of the huntingtin (htt) protein,
facilitating its aggregation. Htt interacts with a variety of membranous structures within
the cell, and the first seventeen amino acids (Nt17) of htt directly flanking the polyQ
domain is an amphiphathic α-helix (AH) lipid-binding domain. AHs are also known to
detect membrane curvature. To determine if htt exon1 preferentially bound curved
membranes, in situ atomic force microscopy (AFM) studies were performed. Supported
lipid bilayers are commonly used as model membranes for AFM studies of protein
aggregation. However, these supported bilayers usually lack curvature. Supported lipid
bilayers with curvature were developed as described in chapter 2. This model bilayer
system was exposed to synthetic truncated htt exon1 peptide (Nt17Q35P10KK), and this
peptide preferentially bound and accumulated to curved membranes, consistent with the
ability of AHs to sense membrane curvature.

1

This chapter is based on “Curvature enhances binding and aggregation of huntingtin at lipid membranes”
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3.1 Introduction: Huntingtin’s disease and Importance of membrane curvature

Huntington's disease, a fatal neurodegenerative disease, is caused by an expansion
of a polyglutamine (polyQ) domain in the first exon of the htt [1]. Lying near the Nterminus of the protein, expansion of polyQ beyond a critical threshold (~35-39 repeat
residues) directly leads to the formation of a variety of htt aggregates, i.e. oligomers and
fibrils, with the eventual formation of inclusion bodies in HD brain tissues [2]. The age of
onset and severity of disease are strongly correlated with the length of the polyQ
expansion [3]. Full length htt is over 3144 amino acids in size; however, a large number
of truncated htt products are produced in vivo via proteolysis,[4-6] and several lines of
evidence suggest that the first exon of htt may play an important role in HD. For
example, the expression of htt exon1 with an expanded polyQ tract causes a progressive
neurological phenotype in transgenic mice [2, 7], and N-terminal fragments comparable
to exon1 are detected in knock-in mouse models of HD that express full-length htt [2, 7]
and in HD patients [5].
Structural analysis of the first 17 amino acids of htt exon1 (Nt17) directly
preceding the polyQ tract suggests it functions as a lipid binding domain as it forms an
amphiphilic α-helix (AH) [8-10]. The addition of Nt17 shifts the aggregation process of
polyQ in free solution to a pathway that includes oligomeric intermediates [11-13].
Further studies suggest that surfaces, including lipid membranes, can further modulate
the aggregation process, favoring the formation of amorphous accumulations of htt exon1
and small oligomers [14, 15]. Targeting the Nt17 domain with other molecules is an
effective way of altering htt aggregation [11, 16]. A polyproline (polyP) domain is
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directly adjacent to the C-terminal side of the polyQ domain in htt. The polyP sequence
also influences the aggregation kinetic, conformational, and structural properties of htt
[17, 18]. The aggregation of htt on model lipid membranes is also modulated by the
presence of the polyP domain [15].
Upon subcellular fractionation of neuron-like clonal striatal cells, ~ 50% of
endogenous htt partitions with membranes [19]. Association of htt with lipids is further
supported by the accumulation of lipid species in htt aggregates in transgenic mouse
models of HD [20, 21]. Beyond playing a role in targeting lipid membranes, Nt17
functions in trafficking htt to the endoplasmic reticulum, mitochondria, Golgi, and
various vesicles [22-24]. N-terminal fragments of htt are observed in membranes that
have been isolated from brain [4]. An apparent correlation of polyQ length with insertion
into lipid membranes, [14, 25] suggests that htt's interactions with lipids may play a role
in HD. In this regard, htt has been shown to disrupt bilayer structure, altering the local
mechanical properties of supported membranes [14, 26].
A variety of protein motifs play a critical role in sensing and targeting specific
physical properties of membranes. In particular, membrane curvature is a physical
property targeted by amphipathic helices (AH) [27-29]. As the Nt17 domain of htt has
been shown to have an amphipathic helical structure as a monomer, [30] fibril, [12] and
when bound to lipids,[9, 10, 12] this study sought to determine if htt preferentially binds
to curved membranes. In recent years, supported lipid bilayers have been increasingly
used as model substrates for AFM studies aimed at understanding protein aggregation on
membranes; [26, 31-36] however, as these supported bilayers are typically flat, it is

77

difficult to account for the potential role of membrane curvature in protein/lipid
interaction using this method. In chapter 2, a system of a model supported lipid bilayers
with both flat and curved regions were developed and validated. This system is exposed
to a model htt peptide to determine if curvature plays a role in the interaction of htt with
lipid membranes. The model, synthetic htt peptide was chosen based on several
considerations: 1) 35 Gln repeats in synthetic peptides is sufficient for aggregation;[13]
2) the polyP domain length (10 prolines) is similar to that directly adjacent to polyQ in htt
exon1; 3) the known lipid-binding properties of Nt17;[22] and 4) this peptide has been
demonstrated to effect lipid membranes in a similar manner to full htt exon1 proteins
[15].
3.2 Materials and Methods
3.2.1 In situ AFM imaging conditions
In situ AFM experiments were performed with a Nanoscope V MultiMode
scanning probe microscope (Veeco, Santa Barbara, CA) equipped with a with a tapping
mode fluid cell , an O ring, and a closed-loop vertical engage J-scanner. Images were
taken with rectangular shaped silicon nitride cantilevers (Vista probes) with a nominal
spring constant of 0.1 N/m (Phoenix, AZ). Typical scan rates ranged from 1-2 Hz, and
drive frequencies of 5 - 6 kHz were used.

3.2.2 Peptide Preparation
A synthetic peptide based on Htt exon1, Nt17Q35P10KK, was obtained via custom
synthesis (Keck Biotechnology Resource Laboratory, New Haven, CT). Disaggregation
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and solubilization of the peptides was achieved based on established protocols.[37]
Briefly, crude peptide was dissolved for 3 h in a 1:1 mixture of trifluoroacetic acid (Acros
Organics) and hexafluoroisopropanol (Acros Organics) at a concentration of 0.5 mg/ml.
Samples were rigorously vortexed, and the solvent was then evaporated off with a gentle
stream of N2. To remove any trace amounts of solvent from the peptide, samples were
placed in a Vacufuge concentrator (Eppendorf). This process produced thin peptide films
that were resuspended in ultrapure water adjusted to pH 3 with trifluoroacetic acid to 200
μM, snap frozen, and stored at −80 °C. These stock solutions were thawed and
immediately diluted with 10 mM Tris HCl buffer to a final concentration of 20 μM and
with a resulting pH of 7.3. The peptides were injected directly into a fluid cell above a
clean silicon substrate decorated with 50 nm silica beads. The surface was continually
imaged once the peptide was injected.

3.3 Results
3.3.1 Htt peptides preferentially bind to curved bilayers.
In chapter 2, it was established that lipid bilayers covered both the curved and flat
regions of the substrate. Here, these supported bilayers with both curved and flat regions
were exposed to a synthetic truncated htt exon1 peptide (Nt17Q35P10KK) (Fig. 1). This
peptide contained a 35 residue long polyQ domain flanked by the lipid binding Nt17
domain and a 10 residue long polyP domain. Two lysines were added at the C-terminus
of the peptide to aid in solubility [37]. Observations were limited to regions of the bilayer
that were confirmed to be completely covered by lipid bilayer as determined by AFM
analysis, prior to exposure to Nt17Q35P10KK. Addition of Nt17Q35P10KK indicated our
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Figure 1. Time lapse AFM images taken in solution of a TBLE bilayer exposed to a
synthetic htt exon1 mimicking peptide ( Nt17Q35P10KK). Images were taken of the
surface (a) before exposure Nt17Q35P10KK and (b-d) at 30 minute increments after
injection of the peptide.
zero time-point for exposure, and no additional protein was added after this initial
injection. For each experiment, Nt17Q35P10KK was freshly prepared and was in a
predominately monomeric state upon initial injection; although, some small aggregates
most likely were present. Control experiments exposing TBLE bilayers to protein-free
vehicle solvents were performed, and no observable morphological changes in the bilayer
were associated with injection of vehicle as assessed by AFM. The binding and
aggregation of Nt17Q35P10KK on the bilayer surface was tracked by AFM imaging for 120
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minutes (Fig. 1). The portions of the surface occupied by beads visibly swelled within 30
minutes of exposure to Nt17Q35P10KK as peptide accumulated on the curved bilayers and
these curved regions continued to expand in volume with time. The increase in volume
associated with the curved regions of the substrate occurred uniformly, as all curved
regions appeared to be accumulating peptide. The accumulation of peptide by the curved
bilayers predominately occurred in the lateral dimension, as an increase in the width of
the regions associated with beads grew more quickly in comparison with the height (see
example cross sections as a function of time in Fig.6e). The flat regions of the bilayer
exhibited morphological changes i.e. became rougher, in discrete regions within the first
30 minutes of exposure; however, unperturbed regions of the bilayer were still observed.
With time, the area of the perturbed regions on the flat bilayers expanded and the
roughness increased, this is indicative of htt binding, aggregating, and disrupting the
bilayer. The height scale of the images presented in Fig.1 was optimized to demonstrate
the binding of Nt17Q35P10KK to the curved bilayers. While a hint of the bilayer
roughening can be observed in these images, adjusting the colormap demonstrates this
more clearly (Fig. 2). A freshly formed bilayer on the flat portion of the substrate has a
smooth appearance with an RMS roughness typically less than 0.2 nm. Exposure to
Nt17Q35P10KK resulted in patches of increased surface roughness on the flat lipid bilayer,
consistent with disruption of the bilayer structure by binding of the peptide. The RMS
roughness of these regions exceeds 0.5 nm, and the roughness increases with time as
more peptide binds and/or aggregates in these regions.
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To quantify and compare the total amount
of Nt17Q35P10KK that had bound to the
curved and the flat regions of the bilayer
respectively, the total volume change of the
different regions was determined by AFM
image analysis. As the flat regions of the
bilayer represented a significantly larger
surface area of the substrate, the change in
volume was normalized per unit area. The
initial volume of each lipid covered bead
before exposure to Nt17Q35P10 ( 𝑉0 ) was
subtracted
Figure 2. (a) AFM image with adjusted
height contrast shows that a synthetic htt
exon1 mimicking peptide (Nt17Q35P10KK)
aggregates on and disrupts the flat regions
of the lipid bilayer. This image was taken
90 minutes after the initial exposure to the
Htt peptide. The regions indicated by blue
perimeters have increased surface
roughness associated with the binding and
aggregation of Nt17Q35P10KK. The green
line in the image corresponds to the height
profile in (b).

for

each

subsequent

measurements (Vt) to determine the volume
change (ΔV) associated with deposition of
peptide on curved bilayers at any given
time. However, there are contributions to
the measured volume of objects measured
by AFM due to the finite size and shape of
the probe tip, often referred to as tip

convolution. This results in the measured volume of any given object in an AFM image
being larger than the true volume of that object. Matlab based simulations of tip
convolution [38] associated with AFM imaging of model beads that systematically
increased in volume were performed to determine the expected error associated with the
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Figure 3. Three dimensional renderings of model objects with increasingly larger
volume are presented. (a) The true shape of the object (b) and the corresponding
convoluted shape of the object after imaging with a tip of radius 15 nm

finite size and shape of the tip in determining the volume of deposited peptide. On this
model, the volume change (ΔV) associated with deposition of peptide on curved bilayers
at any given time point was determined by:

𝛥𝑉 = 𝑉0 − 𝑉𝑡

(1)

A model 50 nm bead (approximated as a sphere, original object) was immobilized on a
3D surface (Fig. 3a). The volume of this bead was systematically increased (expanded
objects) to simulate the accumulation of peptide on a curved membrane supported by a
bead. This was done in such a way that most of the volume was added in the lateral
dimension as opposed to the vertical, which is similar to what was observed when
exposing curved bilayers to peptide in experiment (Fig. 1e). As the exact volume of these
model objects is known, the % increase in the true volume of the feature can be
determined (table 1):
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𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑒𝑥𝑝𝑎𝑛𝑑𝑒𝑑 𝑜𝑏𝑗𝑒𝑐𝑡−𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑜𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝑜𝑏𝑗𝑒𝑐𝑡

Increase in true volume =(

𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑜𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝑜𝑏𝑗𝑒𝑐𝑡

) ∗ 100
(2)

Table 1
% increase in true

% contribution due to

% error in measured

volume

convolution

volume change

0.0

43.1

0.0

6.0

40.4

-3.4

11.4

39.3

2.6

15.9

38.9

7.7

21.9

37.0

9.5

44.5

33.7

12.6

70.1

30.0

11.4

97.2

27.4

11.3

126.8

24.9

10.6

208.3

20.7

10.0

302.0

17.8

9.4

Model AFM tips were constructed as hemispheres with varying radii. Results presented
here are for a 15 nm tip. These tips were used to virtually image the model surfaces to
obtain simulated AFM images with tip convolution (Fig. 8b). The % contribution due to
tip convolution for each model object was calculated as:
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% contribution due to tip convolution=

𝑉𝑡 −𝑉𝑡𝑟𝑢𝑒
𝑉𝑡𝑟𝑢𝑒

× 100.

(3)

where Vt is the measured volume after tip convolution and Vtrue is the true volume of the
model object. Using equation 1, the true volume change and the measured volume change
after tip convolution associated with our model objects was determined. The % error in
the measured volume increase was calculated as follows:

Measured volume error=

𝛥𝑉𝑤𝑖𝑡ℎ 𝑐𝑜𝑛𝑣𝑜𝑙𝑢𝑡𝑖𝑜𝑛 −𝛥𝑉𝑡𝑟𝑢𝑒
𝛥𝑉𝑡𝑟𝑢𝑒

× 100

(4)

where ΔVwith convolution is the change in volume measured after tip convolution and ΔVtrue is
the true change in volume. In short, these simulations indicated that while tip convolution
caused the measured volume to typically be overestimated, this error never exceeded
15%. The increased volume associated with flat regions of the bilayer was measured by
summing up the volume of features observed above the baseline of the unperturbed
bilayer height. By both of these measurements, the volume associated with the initial
deposition of bilayer was controlled for both the curved and flat regions of the surface.
Based on this analysis, Nt17Q35P10KK preferentially accumulated on the curved rather
than the flat regions of the bilayer, even when taking into account the potential 15%
overestimation due to tip convolution of the beads (Fig. 4). Furthermore, shading has
been added to Fig. 4 to indicate what the volume change associated with peptide
deposition would be if there was a 15% overestimation, and this value was still
significantly larger when compared to the amount of peptide deposited on flat regions of
the bilayer. While Nt17Q35P10KK accumulated on both types of surfaces, significant
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Figure 4. Volume of deposited synthetic Htt exon1−mimicking peptide(
Nt17Q35P10KK) on the curved or flat regions of the bilayer. The shaded region
represents the estimated volume of peptide deposited on the curved bilayers after taking
into account tip convolution (percent error assumed to be ≤15% based on simulations

differences (p < 0.05) in the volume of deposited peptide were observed within 30
minutes. The amount of deposited peptide increased linearly for the next hour for both
regions of the bilayer; however, the accumulation of peptide occurred more rapidly on the
curved regions. After ~90 minutes, accumulation of peptide on the curved bilayer
appeared to level off.
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3.4 Discussion
While tapping mode AFM in solution is widely used to study morphological and
mechanical properties of supported lipid bilayers, one of the limitations associated with
comparing these results to physiologically relevant membranes is the lack of membrane
curvature associated with such systems. A potential method to induce curvature in
supported lipid membranes is introducing local curvature in the substrate through
depositing silica nanobeads onto a silicon substrate, and by the process of vesicle fusion,
as discussed in detail in chapter 2.
When exposing these model bilayers to freshly prepared solutions of an Nterminal htt fragment, it was found that the peptide preferentially accumulated on curved
regions of the bilayer. While htt fragments with expanded polyQ domains are
predominately found in nuclear or cytoplasmic inclusion bodies, [7] htt also directly
associates with numerous membranous surfaces, such as mitochondria, endoplasmic
reticulum, tubulovesicles, endosomes, lysosomes and synaptic vesicles, within the cell [2,
39]. The environments provided by these membrane surfaces could influence the
aggregation of htt with expanded polyQ domains, and these membranous structures
exhibit varying degrees of curvature. This curvature may provide nucleation sites for
aggregation by creating local areas of high htt concentration due to enhanced binding.
The accumulation of monomeric htt and/or pre-fibrillar aggregates directly binding lipid
membranes has been shown to disrupt bilayer integrity and induce mechanical changes in
the membrane [14, 15, 26].
Beyond these implications of htt/lipid interactions in disease mechanisms, there
are several membrane-associated functions attributable to htt in which the lipid binding
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properties of Nt17 may play a role. Some of these functions include htt functioning in
cellular adhesion, [40] motility, [41, 42] cholesterol and energy homeostasis, [43] as a
molecular scaffold for coordination of membrane and cytoskeletal communication, [8]
and facilitating micrutobule-dependent vesicle transport [44]. Nt17 facilitates the
trafficking of htt exon1 to membranes associated with the ER, autophagic vacuoles,
mitochondria, and Golgi [22, 23]. Membrane curvature sensing by the Nt17 domain of htt
may represent a mechanistic detail of some of these functions, and disruption of these
normal lipid associated functions of htt may play a role in toxicity associated with
expanded polyQ domains. Supporting the notion that Nt17 directly interacts with lipid
membranes, the binding of htt exon1 to large unilamellar vesicles comprised of PC or a
mixture of PC and PS alters the helical content of the Nt17, and the associated changes in
helical content could be inhibited by an addition of a proline at the 8th residue of Nt17
[22]. Structural studies utilizing solid state NMR suggest that Nt17 has a predominantly
random coil structure in solution and adopts its α-helical structure upon binding lipid
bilayers [9, 10]. Furthermore, the presence of Nt17 in synthetic polyQ peptides was
necessary to bind model TBLE membranes and induce leakage of TBLE vesicles [15].
One potential mechanism to explain how Nt17, which is an AH, preferentially
binds curved membranes is that bilayer curvature introduces a high density of membrane
defects that can act as binding sites. AHs represent a common motif in a variety of
proteins to sense membrane curvature [27-29]. The insertion process of AHs may be
facilitated by lipid packing defects induced by the membrane curvature, resulting in a
higher affinity of the protein for positively curved membranes [28, 45, 46]. However,
recent studies have suggested that the curvature-selective binding of some AHs is due to
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intrinsic properties of the membrane, that is, a higher density of binding sites rather than
a higher affinity of the protein for the membrane [29]. Assuming that the lipid mass is
conserved on both leaflets of a lipid bilayer and that the lipid composition of the bilayer
remains constant, the density of defects within the leaflet of a bilayer associated with
positive curvature would increase with bending [29]. Once a htt monomer (or possibly
small aggregate) binds to the lipid membrane, this creates a site where more htt could
preferentially accumulate through interaction with the immobilized bound peptide. This
notion is supported by previous observations that monomeric htt exon1 proteins
preferentially accumulate onto immobilized pre-formed aggregates, [47] and that htt
exon1 tends to alter the morphology of lipid bilayers in discrete regions that grow in size
with time [14, 15]. These discrete regions of disruption on the flat portions of the bilayer
were also observed in this study. The binding of amyloid-forming proteins to membrane
defects via AHs has been demonstrated for other amyloid-forming proteins, such as αsynuclein [46, 48] and islet amyloid polypeptide [49].
While the data presented here suggests that the presence of bilayer defects
induced by curvature can enhance the initial binding and accumulation of htt on
membranes, several other factors can potentially play a role in regulating the interaction
of htt exon1 fragments facilitated by Nt17 with lipid membranes. For example, several
residues in Nt17 can undergo post translational modifications, such as phosphorylation,
acetylation, and SUMOlyation, and some of these modifications have been shown to
regulate the interaction of htt with specific organelles [22, 50]. Additional affinity-based
components to the interaction of other AHs with lipid bilayers have been experimentally
observed. Such considerations include electrostatics, [51, 52] partitioning of lipid
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components,[53-55] or the presence of other specific recognition motifs [56, 57]. In
particular, electrostatic mechanisms likely play a role in htt/lipid interactions, as htt binds
multivalent phosphatidylinsoitol phospates (PIPs) and has a high affinity for cardiolipin
[25, 58].

3.5 Conclusion
Apart from the lipid membrane curvature, it has become increasingly evident that
there are several that determine the propensity of polyQ proteins to aggregate. Various
factors, including posttranslational modifications may impact polyQ-aggregation process
and its subsequent toxicity. Specifically, htt undergoes a variety of posttranslational
modifications [59]. Acetylation and phosphorylation of threonine-3 are the most
prevalent modifications of htt exon 1, which greatly impacts the aggregation of htt in
cells and in vivo [60]. With AFM as robust imaging tool, detailed insights on the kinetics
of posttranslational modifications on htt exon1 aggregation and the morphological
characteristics of the resulting aggregates can be obtained. The impact of acetylation
modification on htt aggregation is the focus of the next chapter.
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4. Acetylation within the first 17 amino acids of huntingtin exon1 alters
aggregation and binding to lipid membranes 1

Huntington disease (HD) is a genetic neurodegenerative disorder caused by an
expanded polyglutamine (polyQ) domain near the N-terminus of the huntingtin (htt)
protein. Expanded polyQ directly leads to htt aggregation. The first 17 amino acids (Nt17)
in htt is a lipid-binding domain that also promotes diverse aggregate species of htt. Nt17
undergoes a number of posttranslational modifications that can modulate htt’s toxicity,
subcellular localization, and trafficking of vesicles. N-terminal acetylation of htt has been
implicated in the etiology of HD. Given the importance of acetylation in HD, this study
sought to evaluate the impact of lysine acetylation on htt aggregation in solution and on
model lipid bilayers. Acetylation of htt-exon1(51Q), and synthetic truncated htt exon1
mimicing peptides (Nt17Q35P10KK) was achieved using a selective covalent label sulfo-Nhydroxysuccinimide (NHSA) in molar ratios of 1x, 2x, and 3x NHSA per peptide. With
this treatment, all three lysine residues (K6, K9, and K15) in Nt17 were significantly
labeled. N-terminal htt acetylation decreased fibril formation in solution and promoted
the formation of larger globular aggregates. Acetylation strongly altered htt’s ability to
bind lipid membranes. Acetylated htt bound lipid membranes and disrupted lipid bilayer
morphology less aggressively compared to unlabeled htt. Mechanistic insights into how
acetylation alters the interaction of Nt17 with lipid membranes were provided by
computational studies. The results presented here, highlight that N-terminal acetylation
influences the aggregation of htt and its interaction with lipid bilayers.

1

This chapter is based on submitted manuscript “Acetylation alters huntingtin aggregation and
membranes”
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4.1 Introduction: Huntingtin’s disease and post translational modifications.
Huntington’s disease (HD) is a neurodegenerative disorder caused by an
expanded CAG trinucleotide repeat in the IT15 gene that codes for the huntingtin (htt)
protein. This CAG expansion encodes an abnormal stretch of more than 35-40
polyglutamine (polyQ) repeats within the first exon of htt [1]. In HD, the age of onset and
severity in disease is highly correlated with polyQ length [2, 3]. Expanded polyQ
domains in htt are directly implicated in the aggregation of htt into fibrils and a variety of
other structures [4-6]. The polyQ domain is located in the first exon of htt, beginning
with the 18th residue, and substantial evidence points to N-terminal fragments of htt
comparable to exon 1 being involved in HD [7-12].
In HD patients’ brains, mutant htt is detected predominantly in microscopic
inclusion bodies in the cytoplasm and nucleus [10], but it also associates with
membranous

organelles,

including

mitochondria,

endoplasmic

reticulum

(ER),

tubulovesicles, endosomes, lysosomes and synaptic vesicles [13-16]. Approximately half
of endogenous htt partitions with membranes after subcellular fractionation of neuronlike clonal striatal cells [17]. Futhermore, membraneous structures are assimilated onto
the surfaces of htt inclusion bodies in cellular models [17, 18], and htt aggregates
accumulate brain lipids in mouse models of HD [19, 20]. With regards to N-terminal
fragments of htt, Nt17 is required for membrane localization [21, 22] and regulates lipid
binding [23]. Beyond functioning in lipid binding, Nt17 promotes oligomer formation [24,
25], and targeting Nt17 directly is an effective strategy for inhibiting aggregation [24, 26].
In solution, monomeric Nt17 is predominately disordered, as demonstrated by
NMR [25], but circular dichroism (CD) studies suggest that Nt17 contains 10–50% α100
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helical content, depending on buffer conditions [21, 25, 27, 28]. This suggests that Nt17
may adopt multiple configurations. Such a notion is supported by computational studies,
some of which predict that Nt17 can form an α-helix in aqueous solution [29, 30]; others
suggest that Nt17 is predominately unstructured in solution [28, 31-34]. However, the Nt17
domain appears to be α-helical in at least some aggregate forms of htt [26, 35, 36], and it
transitions to an α-helical structure upon self-association [24] or when it interacts with
phospholipids, detergents, or other apolar compounds [21, 25, 27, 37]. Furthermore,
recent IMS-MS experiments suggest the presence of coexisting solution conformers for
Nt17 peptides [38].
Several post translational modifications (PTMs) including proteolytic cleavage,
acetylation, phosphorylation, ubiquitination, and SUMOylation, are associated with HD
pathogenesis [39-41]. Dysregulation of PTMs triggered by expanded polyQ tracts may
lead to aberrant htt interactions [42]. A number of PTM sites are located in the
Nt17domain, with some sites associated with multiple modifications [43]. Specifically,
proteomic mapping by mass spectrometry (MS) identified acetylation sites at K6, K9, and
K15 [44]. This N-terminal acetylation preferentially occurred in htt with polyQ lengths
below the disease threshold, suggesting that decreased acetylation of expanded htt could
play a role in pathogenic mechanisms associated with HD.
Membrane related changes are a clear biochemical feature of HD [45-47]. Htt
predominately localizes to a variety of membranous surfaces within cells, and its strong
association with lipids may play a prominent role in the normal function of htt [45, 48].
Amino-terminal mutant htt fragments have been shown to aggregate on and damage a
variety of phospholipid bilayers, suggesting that phospholipid interactions may play a
101
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role htt-related toxicity [19, 23, 49]. As a result, determining factors that regulate the
affinity of htt for membranes is critical in understanding not only the normal functions of
htt, but also in identifying ways to modify htt/lipid interactions for potential therapeutic
strategies. It is clear that Nt17 influences the aggregation of N-terminal fragments of htt
[24, 26, 35] and their direct interactions with lipid membranes [23, 27, 37, 50, 51].
Furthermore, PTMs within Nt17 have a profound effect not only on htt function and
translocation [52-54], but also on the toxicity associated with mutant htt containing
expanded polyQ domains [42, 43, 55-57]. However, the impact of acetylation of Nt17 on
modulating htt aggregation and its interactions with lipid bilayers is poorly understood.
The aim here is to elucidate the influence of acetylation of Nt17 on these phenomena.

4.2 Materials and Methods
4.2.1 Peptide preparation.
Synthetic Nt17Q35P10KK was purchased from the Keck institute (Yale University)
and stored at −20 °C until later use. The synthetic, model htt peptide used in this study
contains 35 glutamines (which is sufficient for aggregation), [58] a C-terminal
polyproline (polyP) domain that is ten residues in length, and the previously mentioned
Nt17 on the N-terminus. Disaggregation and solubilization of peptides were achieved by a
variation on published protocols [59]. In short, 1.0-mg portions were dissolved in 1.00 ml
of

50/50

trifluoroacetic

acid/hexafluoroisopropanol

(TFA/HFIP)

to

ensure

disaggregation. The samples were aliquoted into 250-µl portions and dried under a steady
stream of nitrogen until most of the TFA/HFIP was removed. The aliquots were then
placed in a centrifugal evaporator for 3 h to ensure removal of all TFA/HFIP. The
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resulting 0.250-mg peptide films were stored at −20 °C until further use. The peptide
films were reconstituted in pH 3 TFA, and then diluted to 20 μM in pH 7 PBS. Labeling
was performed immediately after reconstitution at the three molar ratios. The labeling
reaction was quenched by the addition of 100 µL Tris HCl after a one-minute reaction
time. 50 µL of acetonitrile was added to each sample to prevent aggregation before
enzymatic digestion. 2.0 µL of 1.0 mg/mL chymotrypsin was added to each sample and
allowed to digest overnight at 37°C. Digestion was quenched by addition of 5 µL of
formic acid. Samples were aliquoted and immediately analyzed by LC-MS/MS.

4.2.2 Liquid Chromatography/Tandem Mass Spectrometry.
LC-MS/MS was performed using an Accela binary pump LC coupled to a Q
Exactive mass spectrometer (Thermo Scientific, San Jose, CA). Separation was
facilitated using a Synergi Fusion RP-80 2.0 x 100 mm column, particle size of 4 micron
(Phenomenex, Torrance, CA) with water 0.1% formic acid as solvent A, and acetonitrile
with 0.1% formic acid as solvent B. A 60 minute gradient was used (5 – 100% B over 60
minutes) with a ten minute column re-equilibration between successive runs, at a flow
rate of 0.200 mL/min. A 20 µL sample injection was used for all injections. The mass
spectrometer was operated in a data-dependent mode, where the 5 most intense ions in
each scan were submitted for MS/MS HCD fragmentation. Data analysis was performed
using Thermo Proteome Discoverer (Thermo Scientific). A database containing only the
peptide of interest was generated manually and used as search criteria. The program
searched for both acetylated and unmodified peptide ions of interest within each LC103
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MS/MS dataset. Peak areas for ions that contained the specific lysine residue were
recorded for all labeled and unlabeled ions. Percent modification for each lysine residue
was reported as a percent of the total ion signal for the residue in question:
%𝑀𝑜𝑑 =

∑ 𝑀𝑜𝑑𝑖𝑓𝑖𝑒𝑑 𝑖𝑜𝑛 𝑝𝑒𝑎𝑘 𝑎𝑟𝑒𝑎
∑ 𝑀𝑜𝑑𝑖𝑓𝑖𝑒𝑑 𝑝𝑒𝑎𝑘 𝑎𝑟𝑒𝑎+ ∑ 𝑈𝑛𝑚𝑜𝑑𝑖𝑓𝑖𝑒𝑑 𝑝𝑒𝑎𝑘 𝑎𝑟𝑒𝑎

(1)

4.2.3 Thioflavin T (ThT) assay.
The assay was performed using a Molecular Devices M5 spectrophotometer
(Molecular Devices, LLC, Sunnyvale, CA, USA). Stock ThT (Sigma Aldrich, St. Louis,
MO, USA) was prepared in nanopure water at a concentration of 1.0 mg/ml. Peptide
labeling with NHSA was performed immediately after reconstitution, and immediately
before analysis. 2.0 µL of the stock ThT was spiked into the sample (100 µl total sample
volume/well). Sample fluorescence was monitored using 440-nm excitation and 480-nm
emission wavelengths. Samples were kept at 25 °C for the duration of the assay.
Emission data points were acquired every minute for 6 h for each NHSA concentration.
Background fluorescence was obtained from a blank sample that contained no peptide,
collected simultaneously with the analyte. Each peptide sample was run in triplicate and
averaged. The average background signal was subtracted from each data point in the
spectrum to obtain the actual fluorescence associated with β-sheet formation. Signal was
normalized to the highest intensity value for each trial.
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4.2.4

Purification

of

Glutathione

S-transferase

(GST)-htt-exon1

fusion

proteins.
GST-htt exon1 51Q fusion proteins were purified as described elsewhere [20, 60].
In short, expression of GST-htt fusion proteins was induced in Escherichia coli by
isopropyl β-D-thiogalactoside for 4h at 30oC. The cells were lysed with 0.5mg/ml of
lysozyme. Liquid chromatography (LPLC, Bio-Rad) with a GST affinity column was
used to purify the fusion proteins from the lysate. Relevant fractions to collect and purify
were determined by gel electrophoresis, and purity of fusion proteins was consistently
greater than 95%. Prior to all experiments, solutions with all GST-htt exon1 51Q fusion
proteins were high spin centrifuged at 20000 x g for 30 min at 4oC to remove pre-existing
aggregates. To initiate aggregation, the cleavage of the GST moiety was performed by
the addition of Factor Xa protease (Promega, Madison, WI) for 1h in ice. Experiments
were carried out in PBS buffer.

4.2.5 Acetylation of htt exon1 51Q.
Htt was acetylated using selective covalent label, sulfo-N-hydroxysuccinimide
acetate (NHSA) [61]. Stock solutions of NHSA were prepared in water to make
1.71mg/ml solution. The labeling of htt was carried out in NHSA/htt molar ratios to
achieve 1x, 2x and 3x NHSA labeling for 1 min, and the reaction was quenched by
adding 10mM Tris. The labeling was confirmed by MS. After acetylation, factor Xa
protease was added to each protein sample and allowed to sit in ice for 1 h prior to bilayer
experiments.
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4.2.6 Protein samples for ex situ AFM imaging.
The GST proteins (htt 51Q, + 1x NHSA, +2x NHSA, +3x NHSA) at 20 µM in
Eppendorf tubes were incubated at 37oC and 1400 rpm for the duration of the experiment.
At 0, 1, 3, 5, 8, 24 h after cleavage of GST with factor Xa protease, aliquots (5µl) from
each incubation sample were spotted onto freshly cleaved mica (Ted Pella Inc., Redding,
CA), for 30seconds, washed with 200µl of ultra-pure water and dried gently with a
stream of air. There mica was placed on metal pucks and imaged with AFM.

4.2.7 Preparation of lipid bilayers.
The lyophilized total brain lipid extract (TBLE) (Avanti Polar Lipids, Alabaster,
AL) was reconstituted in 10mM PBS (pH 7.3) with vortexing to a concentration of
1mg/ml. Using liquid nitrogen, the lipid sample went through five cycles of freeze-thaw
to facilitate bilayer and multilayer lipid sheet formation [62]. The lipid samples were then
sonicated for 20 min to facilitate vesicle formation. A 40µL aliquot of 0.5mg/ml TBLE
was added into AFM fluid cell. A 25 µm x 25 µm lipid bilayer formed on the mica
surface via vesicle fusion. The formation of the bilayer was monitored by continuous
AFM imaging. Once fully formed, the bilayer was washed twice with 15µl of PBS to
remove excess lipid vesicles.

4.2.8 AFM imaging conditions.
All AFM experiments were performed with a Nanoscope V Multimode AFM
(Veeco,Santa Barbara,CA) equipped with a closed loop vertical engage J-scanner. For ex
situ AFM experiments, all images were acquired with diving board shaped silicon-oxide
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cantilevers with a nominal spring constant of 40 N/m and resonance frequency around
300 kHz. For in situ AFM experiments, a tapping mode fluid cell with an O ring was
equipped with a rectangular shaped silicon nitride cantilevers (Vista probes) with a
nominal spring constant of 0.1 N/m. The scan rates were set between 1-2 Hz at 512 pixels
per line and drive frequencies of 5 - 6 kHz were used with the set point of 0.70.

4.2.9 Imaging Processing.
All images were analyzed using Matlab with the image processing toolbox
(MathWorks, Natick, MA) [63]. Physical dimensions of aggregates were measured
automatically by (i) importing the images into Matlab, (ii) using a flattening algorithm to
flatten the images to correct for background curvature, (iii) creating a binary map of the
surface to locate individual aggregates using a height threshold, (iv) locating discrete
aggregates by applying pattern recognition algorithms to the binary maps, and (v) finally
the physical features (height, length etc) of individual aggregates were automatically
measured .

4.2.10 Preparation of TBLE/PDA vesicles.
The polydiacetylene (PDA) assay was prepared using protocols previously
described [64-67]. Briefly, TBLE and diacetylene monomer 10, 12 tricosadiynoic acid
(GFS Chemicals, Columbus, OH) in 2:3 molar ratio were mixed in 3 ml of solution of
ethanol /chloroform (1:1) in a round bottomed flask. The solution was dried by rotavap
leaving a thin dry film. This was followed by the addition of 14.8 ml of 1x Tris buffered
saline (heated to 70oC), and sonicated on high for 5 min at 100 W using a sonic
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dismembrator (FischerSci).The suspension was stored at 4oC overnight, then polymerized
by irradiation with 7 lumens (UV analyzer) at 254nm for 10 min while stirring
thoroughly at room temperature giving a blue TBLE/PDA chromatic solution. The
solution was kept in a glass container, covered with foil prior to experiments.

4.2.11 Preparation of PDA/htt sample solutions.
The assay included PDA +1x Tris (negative control), PDA+1x Tris +NaOH (pH
12; positive control), and PDA mixed with each of the four sample solutions described
previously (htt-exon1 (51Q), htt +1x NHSA, htt +2xNHSA, htt +3xNHSA). Each sample
was loaded in a 96 well plate in triplicate to achieve a final protein concentration of
20µM in each well. The kinetic absorbance measurements was recorded for 16 h on
infinite M1000 Pro plate reader (TECAN, Switzerland) at 22oC with 3 sec shaking
between reads .The plate reader was set to record both the blue (640 nm) and the red
component (500 nm) of the spectrum for each sample. Colorimetric response (%CR) was
used as a quantitative measurement of PDA/protein interaction.

4.3 Results
4.3.1 Chemically-induced acetylation occurs at all lysines in Nt17 and inhibits
aggregation.
In htt-exon1 there are three lysine residues available for acetylation that are
located in Nt17 (K6, K9, and K15). To determine their availability for acetylation, model
htt peptides were exposed to sulfo-N-hydroxysuccinimide acetate (NHSA), an established
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agent for labeling primary amines in proteins [68, 69]. The model htt peptide contained
the Nt17 domain, 35 repeat glutamines, a 10-residue polyproline domain, and two Cterminal lysines (Nt17-Q35-P10-KK) to aid solubility. Nt17-Q35-P10-KK was used in place
of the GST-fusion construct to reduce spectral complexity and eliminate ions that
correspond to missed GST-htt cleavages. In cases where MS/MS data was insufficient or
not available, the exact monoisotopic mass of a labeled ion was used for identification of
an ion of interest. If this ion were produced from a peptide of a missed GST cleavage
product, then this method would lead to a false-positive for a labeling event, skewing the
results. As there are three lysines in Nt17, labeling was carried out in molar ratios of 1x,
2x, and 3x NHSA to htt, with quenching of the labeling reaction after 1 min by addition
of 10 mM Tris. Acetylated lysines were verified using chymotrypsin and MS to measure
the relative amount of labeled and unlabeled fragments containing single lysine residues
(Fig. 1a), and ThT assays were run to determine the impact of acetylation on Nt17-Q35P10-KK aggregation (Fig. 1b). Chymotrypsin was selected over other serine proteases
(such as trypsin) as its enzymatic activity is unaffected by substitution of the lysine
primary amine. Overall, K9 was the most readily labeled, followed by K6 and K15. At 1x
NHSA, all three lysines in Nt17 were labeled to some extent, but no more than 30%. With
2x NHSA, K9 was acetylated to a significantly larger extent (69%) than the other two
lysines. At 3x NHSA, K9 acetylation increased to over 80%, and over 60% of K6 was
labeled. Acetylation of K15 increased with larger doses of NHSA, but it was never over
30% acetylated. The two flanking lysines at the C-terminus were not appreciably
acetylated under any dose of NHSA. As acetylation increased,
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Figure 1. Lysines within Nt17 are accessible for acetylation and impact fibril
formation. (a) MS analysis of the extent of lysine acetylation by NHSA in Nt17 for a
model peptide Nt17-Q35-P10-KK. Error bars represent the standard deviation. (b) ThT
aggregation assays demonstrating the impact of lysine acetylation by NHSA on Nt17Q35-P10-KK fibril formation.
aggregation was inhibited in a dose dependent manner. At 1xNHSA, there was a slightly
slower rate of aggregation (Fig. 1). 2x NHSA increased the lag phase with an overall
reduced rate of aggregation. At 3x NHSA, aggregation was significantly decreased. This
inhibition of aggregation suggests that K6 and K9 may play important roles in
aggregation as reduced aggregation was observed once these residues were appreciably
labeled.

4.3.2 Acetylation of Nt17 inhibits htt-exon1 fibril formation.
To determine the impact of acetylation on full length htt-exon1 aggregation, a
mutant htt fragment, that expresses exon1 with 51Q (htt-exon1(51Q)), was exposed to
different amounts of NHSA and the aggregation tracked. Htt-exon1(51Q) was purified
from Escherichia coli as a soluble fusion with glutathione S-transferase (GST) [60]. The
GST moiety was cleaved with a site-specific protease (Factor Xa), releasing the httexon1(51Q) fragment and initiating aggregation [70]. Htt-exon1(51Q) was exposed to
NHSA in molar ratios of 0:1, 1:1, 2:1, or 3:1 in a similar fashion as Nt17-Q35-P10-KK. To
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Figure 2. Addition of NHSA to GST-htt-exon1 (51Q) does not inhibit cleavage of
the GST tag by Factor Xa. (a) SDS-PAGE demonstrating the efficiency of cleaving
the GST tag of the fusion protein that had been acetylated with varying amounts of
NHSA. (b) Densitometry analysis was used to determine the percent of cleaved httexon1 (51Q) as a function of total protein in the presence of varying amounts of
NHSA.

verify that addition of the NHSA would not interfere with the removal of the GST tag,
fusion protein that had been exposed to the different molar ratios of NHSA were
incubated with Factor Xa on ice for one hour and analyzed using SDS-PAGE (Fig. 2).
Densitometry analysis of the resulting gels demonstrated that there was no appreciable
difference in the efficiency of cleaving the GST tag upon addition of NHSA.
Incubation experiments were performed with freshly prepared 20 μM solutions of
htt-exon1(51Q) that had been acetylated by NHSA at the different molar ratios. Aliquots
were removed from the solutions after 1, 3, 5, 8 and 24 h of incubation for AFM analysis
(Fig. 3). In an effort to quantify the effect of acetylation on htt aggregation, AFM images
from all incubations were analyzed by counting the number of oligomers or fibrils per
μm2 at each time point (Fig. 3b-c). For this analysis, aggregates were defined as objects in
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Figure 3. Chemical acetylation of Nt17 in htt-exon1 (51Q) suppresses
aggregation. (a) Representative AFM images taken in air after 5 and 24 h of
incubation of htt-exon1(51Q) alone or labeled with 1x, 2x, or 3x NHSA. Blue
arrows indicate oligomers, and black arrows indicate fibrils. The number of (b)
oligomers and (c) fibrils per unit area observed in AFM images taken of
aggregates formed by htt-exon1(51Q) alone or labeled with 1x, 2x, or 3x NHSA
as a function of time. The error bars represent the standard deviation.

the image taller than 2 nm. Fibrils were distinguished from oligomers by a length-towidth (aspect) ratio filter. Fibrils had an aspect ratio >3; oligomers had an aspect ratio < 3
[63]. Htt-exon1(51Q) incubated without any NHSA quickly formed a variety of
oligomers and fibrils (Fig. 3). The number of oligomers per unit area fluctuated from 1522 without any significant changes over 24 h. The number of fibrils, however, steadily
increased over 24 h. At 1 h, only a small number of fibrils were present, and these
increased in number and grew from several hundred nanometers to > 1 μm in length at
later time points. When htt-exon1(51Q) was labeled with 1x NHSA, there was no
significant difference in the number of oligomers compared to non-acetylated htt112
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exon1(51Q); however, after 8 h, there was a significant decrease in the number of fibrils
observed compared to the control (no acetylation). Increasing the NHSA treatment to 2x
again resulted in no significant change in the number of oligomers observed, but there
was a clear inhibition of fibril formation as early as after 1 h of incubation. Treatment
with 3x NHSA resulted in a significant decrease in the number of oligomers and fibrils as
a function of time. Overall, increasing the ratio of NHSA to htt decreased the number of
fibrils that formed in a dose dependent manner, but only at 3x NHSA were the number of
oligomers significantly affected.
Next, we compared the morphology of aggregates formed under the different
acetylating conditions (Fig. 4). As the lateral dimensions contain appreciable contribution
from the finite size and shape of the AFM probe, comparisons between the heights of
aggregates are presented. Fibrils of htt-exon1(51Q) with increasing acetylation tended to
be shorter, presumably due to a decreased time for fibril expansion due to a longer lag
phase. However, the height along the contour of these fibrils was indistinguishable (~56nm, Fig. 4a), suggesting a similar fibril structure. The size distribution of oligomers
observed varied greatly with increasing acetylation (Fig. 4b). Without any NHSA, the
distribution of oligomer size remained relatively tight with a slight increase in the mode
height from 5-6 nm to 6-7 nm after 24 h. The oligomer size distribution was similar up to
5 h of incubation when 1x NHSA was added, but at 8 and 24 h a pronounced population
of larger oligomers (~9-11 nm) began to form. This second, larger population of
oligomers became more pronounced at earlier time points with increasing amounts of
NHSA. With 3x NHSA, the larger population of oligomers eventually predominated the
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Figure 4. Acetylation of Nt17 in htt-exon1 (51Q) influences the size of aggregates.
Height histograms of (a) fibrils and (b) oligomers observed in AFM images taken of
aggregates formed by htt-exon1(51Q) alone or labeled with 1x, 2x, or 3x NHSA as a
function of time. The number of individual aggregates measured is indicated in each
plot.
size distribution. The increased size of the oligomers formed with 3x NHSA may explain
the significant reduction in the total number of oligomers as more peptide was
incorporated into fewer aggregates.

4.3.3 Nt17Acetylation inhibits htt/lipid interactions.
To determine if acetylation of Nt17 would alter the interaction of htt-exon1 with
lipid membranes, a total brain lipid extract (TBLE)/polydiacetylene (PDA) vesicle lipid
binding assay was performed (Fig. 5a). This colorimetric assay uses mixed vesicles
comprised of phospholipids and polymerized PDA. A rapid, visible color change from
blue to red is induced by direct interaction between peptides and the phospholipid within
the vesicles. The colorimetric response can be used to temporally track peptide-
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Figure 5. Acetylation of Nt17 modulates the interaction between htt-exon1(51Q)
and lipid membranes. (a) TBLE/PDA vesicle binding assay demonstrating the impact
of lysine acetylation by NHSA on the ability of htt-exon1 (51Q) to bind and aggregate
on lipid membranes. (b) An AFM image of a complete, supported, TBLE bilayer on
mica. AFM images of TBLE bilayers taken after 1 and 5 h of exposure to (c) httexon1(51Q), (d) htt-exon1(51Q) + 1x NHSA, (e) htt-exon1(51Q) + 2x NHSA, (f) httexon1(51Q) + 3x NHSA. Insets are zoomed in images of the indicated regions of the
larger images. Blue arrows indicate oligomers present on the bilayer. (g) Quantification
of the RMS roughness associated with disrupted regions of the bilayer and the percent
area of the bilayer that has been disrupted for bilayers exposed to htt-exon1(51Q) alone
or labeled with 1x, 2x, or 3x NHSA as a function of time.

membrane interactions and PDA-based vesicles have been used to study a variety of
biological processes at membrane surfaces, including the binding of amyloid proteins
[65, 67, 71, 72]. A quantitative value representative of the blue-to-red color transition is
obtained by determining the % colorimetric response (%CR), defined as [67, 72]
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%CR = [(PB0 - PBI)/PB0] × 100

(1)

where PB is a red/blue ratio of absorbance (A) defined as Ablue/(Ablue + Ared). Ablue is the
absorbance at the “blue” component in the UV-vis spectrum (≈640 nm); Ared is
absorbance at the “red” component (≈500 nm), PB0 is the red/blue ratio of the control
sample (before induction of color change), and PBI is the value obtained for the vesicle
solution after addition of peptides.
The TBLE/PDA vesicles were exposed to 20 µM htt-exon1(51Q) or httexon1(51Q) that had been acetylated by NHSA (1x, 2x, or 3x), and %CR was measured
for 16 hours (Fig. 5a). Upon exposure to htt-exon1(51Q), there was an initial steady
increase in %CR as TBLE/PDA vesicles peptide bound and aggregated on the vesicle.
Eventually, %CR leveled off to a quasi-steady state value. There was not a significant
change in the %CR comparing exposures of unaltered htt-exon1(51Q) to that which had
been exposed to 1x NHSA. After ~14 h, there was a small decrease in the %CR between
these two samples that was significant. However, as the amount of NHSA was increased
to 2x or 3x, there was a clear dose dependent reduction in the %CR observed, indicating
that acetylation reduced the interaction between htt-exon1 and the lipid membrane.
Although, there is still an appreciable interaction of htt-exon1(51Q) with the lipid
vesicles under all conditions.
To further investigate the impact of acetylation on the interaction of htt-exon1
with lipid bilayers, supported model lipid membranes through fusion of TBLE vesicles
were prepared (Fig. 5b). Supported lipid bilayers preserve many important properties
(i.e., lateral fluidity) of their free membrane counterparts [73, 74], and the interaction of
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Figure 6. Exposure to htt-exon1(51Q) disrupts TBLE bilayers morphologically. A
representative AFM image of a TBLE lipid bilayer exposed to htt-exon1(51Q) is
presented. The colored lines in the image correspond to the profiles of the same color.
The yellow shading on each profile represents the maximum roughness of an
unperturbed TBLE bilayer. Arrows point to regions of the profiles that represent areas
where partial holes or gaps have appeared in the bilayer.

amyloid-forming proteins with these bilayers can be continuously tracked using in
solution AFM. Smooth bilayers (as determined by AFM) were exposed to unmodified
htt-exon1(51Q) proteins or htt-exon1(51Q) that had been acetylated with varying
amounts of NHSA (1x, 2x, or 3x NHSA). To cleave the GST moiety, Factor Xa was
incubated with the GST- exon 1 fusion protein on ice for 1 hour prior to exposure to the
supported bilayer. The resulting htt-exon1 preparations predominately contain monomers
and small oligomers [4, 63]. Upon the initial exposure of the TBLE bilayer to 20M
freshly prepared htt-exon1(51Q), there was noticeable deposition of globular protein
aggregates on the bilayer and regions of perturbed bilayer morphology (evidenced by an
increase in surface roughness), consistent with previous reports (Fig. 5c) [49, 75]. The
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globular aggregates were stable on the bilayer surface as they were identifiable in
consecutive images. The extent (or area) of bilayer perturbed by htt-exon1(51Q)
increased with time. While most of the increased roughness appeared as the accumulation
of protein above the initial bilayer surface, height profiles across these perturbed regions
demonstrates that gaps and cavities within the bilayer also form (Fig. 6), verifying that
bilayer structure was disrupted. This is consistent with previous reports that demonstrated
by calcein dye leakage assays [19] and mechanical changes in bilayers [23, 49, 75] that
htt-exon1 can damage membranes. When TBLE bilayers were exposed to 20 M aliquots
of htt-exon1(51Q) that had been chemically acetylated, similar morphological changes
and globular aggregates compared with those associated with non-modified htt were
observed within the bilayer (Fig. 5 d-f). However, the extent of bilayer perturbation
appeared to be reduced as a function of increasing exposure to NHSA. Interestingly, fibril
aggregates of any of the modified and nonmodified htt-exon1(51Q) proteins were not
observed on the bilayer surface.
In an effort to quantify the extent of interaction between the TBLE bilayer and the
different acetylated or non-acetylated htt-exon1(51Q) proteins, analysis of the AFM
images was performed. First, the root mean squared (RMS) roughness of the perturbed
regions of the bilayer was measured (Fig. 5g). A freshly formed TBLE bilayer has a RMS
surface roughness of 0.3 ±0.05 nm. To prevent error associated with the varying extent of
perturbation of bilayer structure, RMS roughness measurements of areas that had been
destabilized by modified or non-modified htt-exon1(51Q) were restricted only to portions
of the images containing altered morphology. This allows for direct comparison of the
extent of altered bilayer morphology contained within the perturbed regions. Within the
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first hour of exposure to the different acetylated or non-acetylated htt-exon1(51Q)
constructs, regions of the bilayer that were significantly rougher (p<0.01) than
unperturbed bilayer were observed; however, the roughness decreased with increasing
acetylation. The roughness associated with perturbed bilayer regions remained relatively
constant for 4 h; however, there was a pronounced increase in roughness after 5 h of
exposure to non-acetylated htt-exon1(51Q) or htt-exon1(51Q) with 1x NHSA.
As the previous analysis was confined just to regions of the bilayer that exhibited
increased roughness, we next wanted to determine the extent of bilayer perturbation as a
function of protein acetylation. To accomplish this, the percentage of the surface that
displayed any increased roughness was determined (Fig. 5g). While the portion of the
bilayer perturbed by acetylated or non-acetylated htt-exon1(51Q) steadily increased with
time, the percent of the bilayer that was morphologically altered decreased as a function
of increased protein acetylation. The trend corresponded well with the results from the
first 5 h of the TBLE/PDA lipid binding assays. Furthermore, it cannot be determined if
these globular aggregates are comprised of solely peptide or if they contain lipid
components. The mode height of the oligomers observed on the bilayer was 2-3 nm for
all experimental conditions and all time-points; although, larger aggregates increased in
population over 5 h.
Due to all of the potential acetylation sites in htt-exon1 being contained within the
Nt17 and the known lipid-binding properties of Nt17, acetylation may change the affinity
of this domain for lipid membranes. To address this, a series of Nt17 peptides were made
that contained lysine to glutamine mutations to mimic acetylation. In this series of
peptides, there are single, double, and triple mutations. TBLE/PDA lipid binding assays
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Figure 7. Acetylation of Nt17 does not alter the size of oligomers of htt-exon1(51Q)
on lipid bilayers. Height histograms of oligomers observed in AFM images taken of
aggregates appearing on TBLE bilayers formed by htt-exon1(51Q) alone or labeled
with 1x, 2x, or 3x NHSA as a function of time. The number of individual aggregates
measured is indicated in each plot.
were performed to assess the relative affinity of these Nt17 peptides for lipid membranes
(Fig. 8). By excluding the polyQ domain, the change in the %CR in the PDA assay
associated with aggregation can be removed, and the ability of these peptides to bind can
be directly assessed. While htt-exon1 and synthetic peptides containing the polyQ
domains have been shown to disrupt and aggregate on lipid membranes [19, 23, 49, 75],
pure Nt17 peptides do not permeabilize lipid membranes [27]. All of the peptides
containing a single mutation reduced the affinity of Nt17 for the vesicles, with the K9Q
and K15Q mutants having a significantly lower affinity for the membrane compared with
the K6Q mutant. This suggests that K9 and K15 may play a greater role in the interaction
of Nt17 with lipid membranes. The double and triple mutants also reduced the affinity of
Nt17 for the lipid membrane; however, only to a similar extent as the K6Q mutation alone.
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Figure 8. Acetylation-mimicking mutations reduce the affinity of Nt17 for lipid
vesicles. TBLE/PDA vesicle binding assay performed with Nt17 peptides containing
either (a) single mutation or (b) multiple mutations of lysine to glutamine to mimic
acetylation.

As the overall %CR is considerably smaller for the Nt17 peptides compared with httexon1(51Q) (Fig. 5a), aggregation on the vesicle surface appears to be the major
contributor to the %CR associated with exposure to the full htt-exon1.

4.4 Discussion
Although it is clear that polyQ expansion plays a key role in htt aggregation and
toxicity, flanking sequences adjacent to the polyQ domain heavily influence aggregation,
aggregate stability, important biochemical and functional properties of the protein, and
ultimately htt’s role in pathogenesis. In particular, the Nt17 domain of htt influences
localization, aggregation, and degradation of htt in a cellular context [21, 22, 43, 57, 7679]. Due to its ability to form an amphipathic α-helix, Nt17 functions in regulating the
binding of htt to a variety of membranous surfaces [21]. In this study, the impact of
acetylation of Lysine residues within the Nt17 domain of htt on its aggregation and
interactions with lipid membranes was investigated. Acetylation of Nt17 impeded the
formation of htt fibrils and promoted the formation of larger, globular oligomers.
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Furthermore, acetylation lowered the affinity of Nt17 for lipid membranes, reducing
membrane damage associated with exposure to htt. These include altered hydrogen
bonding (both intrapeptide and peptide/phospholipid) and electrostatic interactions. As
aberrant htt/lipid interactions have been implicated in a variety of toxic mechanisms,
understanding how acetylation of Nt17 impact htt aggregation and its interaction with
membranous surfaces could lead to therapeutic intervention with the potential
implications to HD. For example, as acetylation in Nt17 is reduced in htt containing
expanded polyQ domains in comparison with wild-type htt [80] and our data indicates
that acetylation reduces the affinity of htt for lipid membranes, acetylating Nt17 may
have a protective effect against htt/lipid interactions.
Computational studies performed in the lab of Dr. Silvina Matysiak at the
University of Maryland suggest that the reduced affinity of Nt17 for lipid membranes
caused by acetylation may be due to a number of factors associated with removal of the
positive charge on lysine. The conformational dynamics of individual Nt17 domains with
differing acetylated lysines in the presence of DOPC lipid bilayers were characterized via
a computational approach using atomistic molecular dynamics. The aim of these
simulations was to examine early events in the surface binding of Nt17 domain. Along
with the wild type Nt17 sequence, three acetylation states were studied: Nt17with K9
acetylated (Nt17-ACK9); Nt17with K6 and K9 acetylated (Nt17-ACK6/9); Nt17 with K6,
K9, and K15 acetylated (Nt17-ACK6/9/15). Simulations of each peptide interacting with
DOPC bilayers were run for 200 ns. With unmodified Nt17, phenylalanine17 (F17) tended
to insert into the membrane first, and this occurred within the first 50 ns of the
simulation. Once F17 inserted into the membrane, hydrogen bonds with the membrane
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were then formed by nearby K15 and serine16 (S16). For the peptides containing various
amounts of acetylation, F17 sometimes associated with the membrane (replicate 1 for
Nt17-ACK9 and replicate 1 and 2 for Nt17-ACK6/9/15); however, this association tended
to be transient compared to the non-acetylated peptide. With acetylation, interaction
between the peptides and membrane would sometimes be initiated by residues 1-3, and
this interaction was accompanied by hydrogen bond formation between threonine3 (T3)
and the membrane. The stability of this interaction mediated by residues 1-3 was
variable, as sometimes the peptide would remain bound to the membrane and other times
the peptide would detach. Due to the transient nature observed in simulations of the
interaction of different Nt17 peptides and the DOPC bilayer, the energetics of these
interactions was determined. Attractive electrostatic interactions of significant magnitude
(-300 to -600+ kJ/mol) were often observed, but these were usually insufficient to cause
permanent peptide association with the membrane. For permanent peptide association
with the membrane, the magnitude of van der Waals interactions typically needed to
exceed the magnitude of electrostatic interactions between the peptide and membrane.
The largest contribution to van der Waals interactions between the peptide and membrane
comes from hydrophobic residues.
Nt17 directly influences the abnormal aggregation of mutant htt. Specifically, Nt17
has been implicated in the initial stages of htt-exon1 aggregate formation [21, 26, 30, 36,
81]. As such, a variety of aggregation mechanisms have been proposed that are mediated
by Nt17, with most supporting Nt17 self-association playing a key role in the formation of
small, α-helix rich oligomers [25, 28, 82], suggesting that Nt17 promotes fibril formation
through an oligomer mediated pathway [36, 51, 83]. With oligomers being widely
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considered as important toxic species in HD, Nt17 directed oligomerization could play a
vital role in htt-related toxicity. Indeed, self-association of Nt17 represents the ratedetermining step in the formation of htt-exon1 oligomers in cellular models [24, 84].
Here, it was demonstrated that acetylation of Nt17 slows htt aggregation and promotes the
formation of larger oligomeric species. There are several plausible mechanisms that could
explain this observation. One scenario is that acetylation promotes the formation of
distinct htt oligomers that are off pathway to fibril formation. Alternatively, it is possible
that acetylation stabilizes the α-helix rich structure of the oligomers, delaying the
transition to fibrils structures and providing time for the oligomers to increase in size by
accumulating more monomers into the aggregate [24, 26, 85-92]. Other PTMs within
Nt17 have already been shown to alter htt aggregation. For example, there are three
phosphorylatable sites in Nt17: T3, S13, and S16, and several studies have found that htt
phosphorylation is associated with reduced levels of mutant htt toxicity [39, 57, 77, 78,
93-95]. Phosphorylation mimicking mutations of T3 enhanced htt aggregation in cultured
cells and reduced lethality and neurodegeneration in Drosophila models of HD [57].
Phosphorylation-mimicking mutations of S13 and S16 significantly slowed htt
aggregation and reduced fibril stability; however, fibril structure was not significantly
changed [26, 77]. Interestingly, phosphorylation can regulate other PTMs, such as
acetylation, and serve as a mechanism to target proteins for degradation [96].
Phosphorylation of S13 has been shown to influence acetylation at K9 [78]. It was also
demonstrate here, that chemically acetylating lysines within Nt17 also can slow
aggregation into fibrils without significantly altering the fibril structure. This finding
further support the notion that Nt17 plays an important role in htt aggregation and, more
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specifically, that targeting the charged lysines within Nt17 may be a viable strategy for
modulating aggregation for therapeutic purposes.
Full-length htt is a multi-domain protein that has been implicated with numerous,
distinct cellular functions. With regards to the potential specificity of Nt17 for membranes
of different composition, many membrane-associated functions are attributable to htt,
such as cellular adhesion [97], motility [98, 99], cholesterol and energy homeostasis
[100], molecular scaffolding for coordination of membrane and cytoskeletal
communication [47], and facilitating microtubule-dependent vesicle transport [48].
Acetylation of Nt17 may play a role in regulating these activities. The trafficking of httexon1 between membranes associated with the ER, autophagic vacuoles, mitochondria,
and Golgi appear to be facilitated by Nt17 [21, 22]. Trafficking of htt to specific subcellular compartments, for example the nucleus [101, 102], can have a strong influence in
htt-related toxicity. The Nt17 domain can form an amphipathic α-helix (AH) [26, 35, 36],
and number of biophysical functions are associated with AHs [103], including the ability
to detect and bind highly curved lipid membranes [104-106]. As AHs tend to bend
membranes weakly, their interaction with lipids can be easily regulated. With the large
number of potential sites for post-translational modification, including acetylation,
contained within Nt17, regulation of htt/lipid interactions via Nt17 may play a role in the
trafficking of htt within the cellular environment. As such, the altered affinity upon
acetylation of Nt17 for lipid membranes could play a role in trafficking htt within cells,
with potential implications for both htt’s normal function and toxicity. Such a scenario
has been demonstrated for phosphorylation of Nt17, which can affect the nuclear export of
htt [21, 107]. It was also shown that acetylation of K9 plays a critical role clearance of htt
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via the proteasome and lysosome [78]. As a result, the acetylation of Nt17 and its
modulating effect on membrane affinity may play a role in a variety of normal functions
of htt. [27, 108, 109]
In a theoretical AH, lysines 6 and 15 would be positioned at the interface between
the hydrophilic and hydrophobic faces. It would appear that residues located in this
interface may play a critical role in the ability of Nt17 to bind membranes. Simulations of
htt peptide fragments associated with lipid membranes indicate that K6 and K15 form
many hydrogen bond with bilayer components [34]. All atom simulations demonstrated
that

K6

and

K15

often

form

salt-bridges

with

phospholipids;

however,

K9 was predominately involved in intramolecular salt-bridges with glutamic acid
residues within Nt17 [50], suggesting that perturbing these residues would likely impact
Nt17’s ability to bind membranes. A combination of experiments and simulations have
indicated that the structure and orientation of Nt17 on membranes is mainly influenced by
the sequestration of nonpolar residues into the hydrophobic core of a membrane;
however, membrane composition influences the affinity of Nt17 for phospholipid bilayers
via specific electrostatic interactions [34, 50]. Collectively, this suggests a potential role
for charged lysines in Nt17 selectively targeting membranes of specific phospholipid
compositions, and removing their charge via acetylation could represent a mechanism to
regulate this specificity. In this regard, mutating charged residues in Nt17, including the
lysines, to alanines alters the localization of huntingtin within cells [21]. Furthermore,
acetylation of a lysine (K444) beyond htt-exon1 has been implicated in autophagic
removal of mutant htt [110]. Acetylation within Nt17 may play a similar role by
regulating htt’s interaction with lipid membranes [111].
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Beyond acetylation, SUMOylation and ubiquitination can also occur at lysine
residues within Nt17 and may also play a role in regulating the interaction of htt with
membranes. SUMOylation is implicated to play a role in HD pathogenesis in both cell
and animal models [43, 55]. Specifically, SUMOylation at K6 and K9 reduce aggregation
in cultured cells and exacerbate toxicity in Drosophila HD models [43]. Ubiquitination
competes for the same lysine residues as SUMOylation, but it is associated with reducing
mutant htt toxicity by tagging it for degradation by the ubiquitin proteasome system
(UPS) [112]. As these other PTMs, are known to be involved in htt translocation within
cells [21, 113]. Interestingly, mutating the lysine residues in Nt17 to arginine reduces
cytotoxicity of Drosophila models of HD [43]. This reduction in cytotoxicity was
attributed to the lack of lysine residues available for SUMOylation. Acetylation of lysine
residues is a known mechanism to regulate the SUMOylation of proteins [114].
Furthermore, proteomic mapping by MS verified that K9 is appreciably acetylated in
mammalian cell lysates [44]. The role of K9 acetylation has not yet been fully evaluated;
however, acetylation of Nt17 may function in to regulate SUMOylation, modulating
toxicity associated with SUMOylation of htt [110].

4.5 Conclusion
As the function, localization, and aggregation of htt have all been linked to Nt17,
there is a need to identify at a mechanistic level how Nt17 influences the formation of
toxic aggregates and its interaction with membranes. Here, it was demonstrated that
lysine residues play an important role in both aggregation and membrane binding, and
this role can be affected by removal of lysine’s positive charge via acetylation. As
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acetylation in Nt17 is known to occur naturally [44, 110], the biophysical impact of this
PTM could be important in htt’s normal function, as well as have a modulating effect on
toxicity related to mutant htt. Such knowledge is important because it could lead to better
defined therapeutic targets (in addition to the polyQ tract) and strategies to treat HD.
From the ongoing discussion, the importance of htt aggregation in HD has long been well
articulated, and lipid bilayers have been shown to influence the aggregation of a variety
of N-terminal htt fragments However, specific lipid components, such as cholesterol
[115], sphingomyelin and gangliosides (GM1) can modulate htt aggregation on lipid
bilayers as well.
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5. Outlook: Other relevant post translational modifications and small molecules as
potential modulators of huntingtin aggregation.
The work presented in this dissertation was aimed at elucidating interactions of htt
with lipid membranes from both a physical and biochemical perspective. It starts with
development and validation of supported lipid bilayers with curvature, followed by
investigating the impact of membrane curvature on synthetic truncated htt exon 1
mimicking peptides (Nt17Q35P10KK) on aggregation. This was followed by expounding
the role of acetylation on huntingtin aggregation, both kinetically and morphologically in
the presence of lipid membranes. The major goal of these studies was to understand
physicochemical aspects and molecular mechanisms associated with aggregation in the
presence of cellular and subcellular surfaces, particularly lipid membranes. The ultimate
goal was to understand potential ways to prevent or slow down mutant huntingtin
aggregation, and eventually leading to the development of therapies since there is no
widely effective preventative or therapeutic treatments for HD. A broad range of research
tools and spectrophotometric assays such ThT and PDA were employed in this study.
However, owing to its robust ability to provide particularly useful insights related to
neurodegenerative diseases, AFM was utilized as the primary tool in my studies. AFM
has the unique ability to be operated in air (ex situ) and in solution (in situ), allowing
direct probing of biological samples at solid-liquid interfaces, under nearly physiological
conditions.
In future, it is important to investigate how the changing the composition of lipid
bilayers by exogenously adding monosialotetrahexosylganglioside known as GM1,
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influences htt binding and aggregation on lipid membranes. Several other factors that can
potentially regulate the aggregation of htt at lipid need further investigation. One of such
factors is the role of several other important post translational modifications (PTMs) on
htt aggregation on lipid bilayers. Phosphorylation and SUMOylation are some of the
modifications that have been implicated in HD pathogenesis; however the impact of these
modifications on htt aggregation on lipid membranes has not yet been evaluated. Finally,
apart from PTMs, there is increasing evidence that small molecules, heat shock proteins
(HSPs) included, could counteract common pathological mechanisms that take place in
neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson's disease (PD)
and HD. It is important to understand how such molecules would interfere with htt’s
potential to form toxic oligomeric assemblies on lipid membranes.

5.1 Work in progress: Lipid components modulates huntingtin aggregation on lipid
membranes
The brain and membrane of neurons are enriched in different kinds of fats and/or
lipids. GM1 which is a major component of lipid rafts is a notable example. In the brain ,
GM1 have a plethora of functions , ranging from cell signaling [1] , to neurotransmission
[2], suggesting that even a small reduction in GM1 levels will likely have a huge
physiological impact on HD neurons.

In 2010, Sipione and coworkers from the

University of Alberta, Canada, observed a reduction in the synthesis of GM1 in a variety
of HD animal models as well as in fibroblasts in HD patients [3]. They further showed
that neuronal cells with decreased GM1 are more susceptible to programmed cell death
leading to neurodegeneration. What was even more intriguing about these studies is that
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administration of GM1 by continuous infusion into YAC 128 mice, not only restores the
GM1 levels but reverses cell apoptosis, leading to improved motor function and complete
reversal of the impairment in YAC 128 mouse HD models [3, 4]. There could be several
mechanisms to explain this restoration in motor function in symptomatic mice. GM1
induces serine S13 and S16 phosphorylation, which could explain the mechanism of this
restoration [3-5]. However, since neurons are primarily composed of lipid membranes,
another mechanism might lie in the role of lipid membranes in HD. Considering the
importance of these finding, together with the role of GM1 in brain neurons, and how
lipid membranes are important in HD pathogenesis, it is therefore of paramount
importance to understand how exogenous added GM1 affects htt aggregation on lipid
bilayers.

5.1.1 Cholesterol and GM1 alters the extent of htt-exon1 binding to lipid vesicles as
determined by TBLE/PDA binding assay.
Prior to the GM1 experiment, the impact of added cholesterol on TBLE lipids was
evaluated as preliminary work. To verify that altering the lipid composition of TBLE
would modulate the interaction of htt-exon1 with lipids, a TBLE/PDA vesicle lipid
binding assay performed. As described in chapter 4, PDA is a colorimetric assay in which
mixed vesicles composed of lipids and polymerized chromatic PDA lipids exhibit rapid
visible color changes from blue to red prompted by interactions between biomolecular
species and the phospholipid components within the vesicles. The colorimetric response
can be used to quantify protein−membrane interactions. The TBLE/PDA vesicles were

5.

146
Outlook: Other relevant post translational modifications and small molecules as
potential modulators of huntingtin aggregation.

Figure 1. Percent colorimetric response (%CR) of TBLE/PDA vesicles containing
various amounts of cholesterol upon exposure to htt-exon1 (51Q) plotted as a function
of time. Error bars indicate one standard deviation (n = 3). The highlighted area
indicates the time frame accessible with AFM experiments

systematically enriched with 0% (pure TBLE), 10%, 20%, or 30% cholesterol or 0%
(pure TBLE), 5%, 10%, or 15% GM1 by mass. These vesicles were exposed to htt exon1
protein and colorimetric response (%CR) was measured for 16 h .Characteristically, there
is an initial steady increase in %CR as TBLE/ PDA vesicles are exposed to htt-exon1.
The %CR tends to level off with time to a steady state. As the exogenous cholesterol or
GM1 content was enhanced from 0% to 30% and 0% to 15% respectively, the binding of
htt-exon1 (51Q) to the vesicles was reduced, highlight that lipid composition modulates
htt aggregation on membranes (Fig.1 and Fig.2 respectively). The quasi-steady state
%CR is also significantly smaller in a cholesterol or GM1 dose-dependent manner,
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Figure 2. Percent colorimetric response (%CR) of TBLE/PDA vesicles containing
various amounts of GM1 upon exposure to htt-exon1(51Q) plotted as a function of
time. Error bars indicate one standard deviation (n = 3).

indicating that cholesterol and GM1 reduces htt-exon1 (51Q) overall binding to and
insertion into lipid membranes. The complete influence of cholesterol on the aggregation
of htt on lipid membranes supported TBLE bilayers containing various amounts of
cholesterol were further studied using AFM, and the findings have already been
published.
For GM1 studies, as in cholesterol, further studies to explore the impact of GM1
on the aggregation of htt on supported TBLE bilayers containing various amounts of
GM1 were conducted. Lipid bilayers were exposed to htt-exon1 and continuously imaged
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Figure 3. GM1 alters the interaction of htt with supported lipid bilayers. Increasing
the GM1 content of lipid bilayers reduces htt aggregation.

using in situ AFM, allowing for the direct tracking of protein aggregation on the bilayer.
Bilayers comprised of pure TBLE, TBLE + 5% GM1, and TBLE + 10% GM1 were used.
As shown in Fig.3, as GM1 is enriched, the bilayers slow down htt aggregation,
suggesting that GM1 could one potential way to control aggregation of htt on lipid
bilayers. This supports other studies, which reported that restoring GM1 levels in HD
mice, prevents the striatal cells from apoptosis.
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5.2 Future studies:
5.2.1 Post translational modifications (PTMs) on huntingtin aggregation.
There are other important PTMs on Nt17 that could be crucial modulators of htt
aggregation and toxicity. The commonly studied ones are SUMOylation and
phosphorylation [6-8]. SUMOylation is the enzymatic covalent attachment of SUMO
(small ubiquitin-like modifier proteins) to the lysine residues of a target protein. SUMO
are 11kDa proteins that are highly conserved in a variety of species and can be
enzymatically reversibly attached to lysine residue of htt [9, 10]. The SUMO conjugation
pathway is a three step process involving the use of the heterodimer E1 activating
enzyme (Ubc2/ Aos1) , an E2 conjugating enzyme (Ubc9) and the E3 ligating enzymes
[11, 12]. The Nt17 domain of htt exon 1 contains three potential lysine SUMOylation
sites, (K6, K9 and K15), and this domain also functions in lipid binding. The
SUMOylation of lysines 6 and 9 (K6, K9) in the drosophila HD model expressing htt was
found to enhance neurodegeneration [13] ,while in cultured striatal neurons,
SUMOylation stabilizes htt exon 1 and decreases its aggregation. It is evident that
SUMOylation has been linked to HD pathogenesis [13-16], but the mechanistic details is
often still poorly understood [13, 15] , and the question still remains, what is the
mechanism of pathology? Htt is found in association with brain lipids [17, 18] and
membranes in cells [19], and PTMs are thought to regulate the lipid/htt interaction [20]. It
has also been reported that various cellular components as well as lipids modulates htt
aggregation and toxicity [21-23]. The studying of SUMOylation on htt’s interaction with
lipid membranes has not yet been explored. SUMOylation has been involved in the
trafficking of htt, and this involves the interaction of htt with lipid vesicles. In subsequent
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projects, it therefore important to investigate the impact of SUMOylation on htt
aggregation at lipid interfaces in order to get mechanistic details of how SUMOylation
influences htt aggregation and how SUMOylated htt interacts with lipid membranes with
potential implications to HD.
Phosphorylation is another extensively studied PTM in which a phosphate group
or a phosphate mimics is added to the threonine or serine residues of a protein. In context
of htt exon 1, the Nt17 has three phosphorylation sites, threonine 3 (T3) and serines 13 and
16 (S13 and S16). It was shown that phosphomimetic mutation of S13 and S16 by
aspartic acid substitution, resulted in decreased toxicity of mutant htt in different animal
models of HD possibly by changing protein conformation and function [5, 24, 25]. Since
surfaces, particularly lipid membranes, play important roles in neurodegenerative
diseases, it is imperative to understand how htt phosphorylation modulates the protein
aggregation at lipid interfaces.

5.2.2 Targeting huntingtin Nt17 with small molecules
The Nt17 domain inn htt exon 1, both in free solution and in the presence of lipids,
has been found to influence the formation of various aggregate species including the
small, highly diffuse, and more toxic oligomers [26, 27]. One of the several ways to slow
down protein aggregation or change aggregation pathway is by blocking Nt17 or making
itin unavailable for self-association [26, 28-30]. From previous studies, polyproline
(polyP) PPII type helix can have a regulatory effect on aggregation Nt17 [31].
Collaboratively I carried out preliminary studies (unpublished) on how polyP peptides
interact with Nt17 of htt exon 1. Htt exon 1 was co-incubated with polpP peptides at
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Figure 4. Representative AFM images: Images of htt exon 1 at different type points
after incubation with polpP and Nt17

37oC and incubated for 24hours to allow aggregate formation. As shown Fig.4, htt exon
1 forms well defined fibrils in a time –dependent manner. After incubation with Nt17 and
polyP, the fibril formation is greatly reduced. This is in agreement with previous
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observations in which oligomers are observed when htt is incubated with polyP,
suggesting that polyP peptide has inhibitory effect on amyloid formation [5]. This could
be due to the polyP peptide interacting with the polyQ domain, stabilizing it and prevents
the transition to β-sheet structure.
It has further been reported that under bulk conditions, several amyloid inhibitors
prevent the formation of aggregate forming species in neurodegenerative [32]. It has also
become evident that amyloidal species such as oligomers and fibrils exert their toxic
effects at cellular membranes than in bulk solution. Studying how small molecules such
heat shock proteins (Hsc70), EGCG, or curcumin interact with htt at the phospholipid
interface could provide critical information on mechanisms by which such molecules
inhibit amyloid formation associated with neurodegenerative. In a separate study, fatty
acid metabolism and its compartmentalization appeared disordered in individuals with
HD [33]. Fatty acids composition has also been implicated in the fluidity of lipid
membranes and HD patients have altered membrane fluidity. The precise mechanism on
how omega-3-fatty acids contribute to HD pathology especially on sub-cellular surfaces,
is not well understood, and needs to be further attention.

5.3. Concluding remarks and Perspectives
Huntington’s disease is a fatal, neurodegenerative disorder caused by an
expansion of the polyQ tract in first exon 1 of htt. It is slightly more than two decades
after the discovery of the IT15 gene, and several strides in HD have been yielding very
promising results but no effective treatment has been identified to date, and much more
remains to be understood about HD pathogenesis. The results presented in this
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dissertation provide some invaluable insights into some of the physicochemical properties
of htt aggregation both in bulk solution and at lipid interface with potential implication
for HD.
In the first and second part of my PhD work, supported lipid bilayers comprised
with curved and flat regions to demonstrate that membrane curvature plays an important
role in htt aggregation were developed and validated. AFM in solution is a widely
valuable technique to study morphological and mechanical properties of supported lipid
bilayers, but one of the limitations associated with comparing these results to
physiologically relevant membranes is the lack of membrane curvature associated with
such systems. When exposed this system of bilayer to an N-terminal htt fragment, the
peptide preferentially accumulated on curved regions of the bilayer. This accumulation
and disruption may represent a mechanistic detail of disruption of the normal lipid
associated functions of htt may play a role in toxicity associated with expanded polyQ
domains. Apart from physical properties of membranes, several chemical properties can
potentially play a role in regulating the interaction of htt exon1 fragments facilitated by
Nt17 with lipid membranes. This took me to my third project on how acetylation
modulates the binding of htt to lipid membranes. It was demonstrated that lysine residues
play an important role in both aggregation and membrane binding, and this role can be
affected by removal of lysine’s positive charge via acetylation. The biophysical impact of
this PTM could be important in htt’s normal function, as well as have a modulating effect
on toxicity related to mutant htt, and could lead to better defined therapeutic targets.
Finally, adding small amounts of exogenous Cholesterol and GM1 to TBLE bilayers was
found to be another way to slows down htt aggregation.
5.

154
Outlook: Other relevant post translational modifications and small molecules as
potential modulators of huntingtin aggregation.

Overall, the findings presented here further underpinned the groundwork of HD
research, with the eventual goal of providing insights for the development of therapeutic
targets and treatment of this devastating disease. Considering the emerging impact of
small molecules in neurodegenerative diseases, further studies will be required to
understand the mechanistic of roles of these molecules (EGCG, curcumin, Hsc70) on htt
aggregation at lipid interfaces other than bulky solution as this could have an enormous
importance in HD therapeutic development.
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